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ABSTRACT
The recently discovered neuropeptide orphanin FQ (OFQ), and its opioid receptor-like
(ORL1) receptor, exhibit structural features suggestive of the µ, k, and d opioid systems. The
anatomic distribution of OFQ immunoreactivity and mRNA expression has been reported
recently. In the present analysis, we compare the distribution of orphanin receptor mRNA
expression with that of orphanin FQ binding at the ORL1 receptor in the adult rat central
nervous system (CNS). By using in vitro receptor autoradiography with 125I-[14Tyr]-OFQ as
the radioligand, orphanin receptor binding was analyzed throughout the rat CNS. Orphanin
binding sites were densest in several cortical regions, the anterior olfactory nucleus, lateral
septum, ventral forebrain, several hypothalamic nuclei, hippocampal formation, basolateral
and medial amygdala, central gray, pontine nuclei, interpeduncular nucleus, substantia
nigra, raphe complex, locus coeruleus, vestibular nuclear complex, and the spinal cord. By
using in situ hybridization, cells expressing ORL1 mRNA were most numerous throughout
multiple cortical regions, the anterior olfactory nucleus, lateral septum, endopiriform nucleus,
ventral forebrain, multiple hypothalamic nuclei, nucleus of the lateral olfactory tract, medial
amygdala, hippocampal formation, substantia nigra, ventral tegmental area, central gray,
raphe complex, locus coeruleus, multiple brainstem motor nuclei, inferior olive, deep
cerebellar nuclei, vestibular nuclear complex, nucleus of the solitary tract, reticular forma-
tion, dorsal root ganglia, and spinal cord. The diffuse distribution of ORL1 mRNA and binding
supports an extensive role for orphanin FQ in a multitude of CNS functions, including
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motor and balance control, reinforcement and reward, nociception, the stress response, sexual
behavior, aggression, and autonomic control of physiologic processes. J. Comp. Neurol.
412:563–605, 1999. r 1999 Wiley-Liss, Inc.
Indexing terms: receptor autoradiography; in situ hybridization; mRNA; mapping; nociceptin
The initial expressional cloning of the mouse the d opioid
receptor (Evans et al., 1992; Kieffer et al., 1992) demon-
strated that it is a member of the G-protein family of
receptors with seven transmembrane domains. This discov-
ery led not only to further characterization of the d opioid
receptor, but also to the identification of cDNA’s encoding µ
and k opioid receptors that were similar to those character-
ized in brain homogenate binding assays and peripheral
tissue bioassays (Chen et al., 1993; Fukuda et al., 1993;
Meng et al., 1993; Raynor et al., 1993; Thompson et al.,
1993; Wang et al., 1994; Yasuda et al., 1993, 1994; Befort et
al., 1994; Kozak et al., 1994). In addition to identifying
cDNAs for the µ, k, and d opioid receptors, homology
screening of cDNA libraries and polymerase chain reaction
amplification revealed a novel member of the opioid recep-
tor family referred to as the opioid receptor-like (ORL1)
receptor, also known as the orphanin FQ receptor (Bunzow
et al., 1994; Chen et al., 1994; Marchese et al., 1994;
Mollereau et al., 1994; Fukuda et al., 1994; Wick et al.,
1994; Wang et al., 1994; Lachowicz et al., 1994). Func-
tional studies of this receptor have demonstrated that,
similar to opioid receptors, its activation stimulates GTPgS
binding and inhibits adenylate cyclase (Wu et al., 1997).
The ORL1 receptor has an overall amino acid identity of
47% when compared across the opioid receptors, and
within the transmembrane domains, the level of identity
increases to 61–64% (Bunzow et al., 1994). Other struc-
tural features that are conserved within the ORL1 and
opioid receptors include the multiple glycosylation sites in
the N terminal domain, aspartate residues in transmem-
brane regions 2 and 3 that may be important for agonist
binding, cyclic AMP-dependent phosphorylation sites in
the third intracellular loop, and several postulated palmi-
toylation sites in the C terminal extracellular domain. In
addition to the high levels of amino acid homology across
the ORL1 and opioid receptors in the transmembrane
domains, the receptors share a high degree of identity in
the three cytoplasmic loops. All four receptors are also
negatively linked to adenylate cyclase (Bunzow et al.,
1994; Fukuda et al., 1994; Lachowicz et al., 1994). The
greatest amino acid divergence between the receptors is
seen in the N terminal and C terminal domains, extracellu-
lar loops 2 and 3, and transmembrane region 4 (Mollereau
et al., 1994). Amino acid mutation analysis suggests that
the ORL1 receptor can bind opioid agonists with single
amino acid changes in transmembranes 5, 6, and 7 (Meng
et al., 1996; Mollereau et al., 1996a; Seki et al., 1998).
Despite the degree of amino acid and structural conserva-
tion across the orphanin FQ and opioid receptors, the
orphanin FQ receptor does not bind any opioid peptide or
alkaloid with high affinity (Bunzow et al., 1994; Chen et
al., 1994; Fukuda et al., 1994; Lachowicz et al., 1994; Wick
et al., 1994; Ma et al., 1997; Nicholson et al., 1998). In
addition, opioid ligands other than etorphine fail to inhibit
forskolin-stimulated cyclase accumulation in cells stably
transfected with the orphanin FQ receptor (Mollereau et
al., 1994).
Early Northern blot analyses suggested the presence of
three ORL1 receptor transcripts, with mRNA bands of 3.3,
7–10, and 15–23 kb (Fukuda et al., 1994; Lachowicz et al.,
1994; Wick et al., 1994). Recent binding studies in mouse
brain provide further biochemical evidence for the possible
presence of heterogeneous ORL1 receptors (Mathis et al.,
1997), and the identification and differential regional
expression of five ORL1 receptor splice variants in the
mouse brain has been reported (Pan et al., 1998). The five
variants include two previously reported, and three addi-
tional splice forms. Insertions noted in the new variants
correspond to the region between transmembrane region 1
and the first intracellular loop, a splice site common to the
other opioid receptors.
In situ hybridization studies that use cDNA for the
ORL1 receptor suggest that it is widely distributed through-
out the rat forebrain, brainstem and spinal cord, but
conspicuously absent in the striatum and cerebellum
(Bunzow et al., 1994; Fukuda et al., 1994; Lachowicz et al.,
1994; Mollereau et al., 1994; Wick et al., 1994). In addition
to the central nervous system (CNS), orphanin receptor
mRNA has also been detected in the intestine, vas defer-
ens, and spleen, with none found in the heart, kidney, or
lung (Wang et al., 1994; Lachowicz et al., 1994). The
paucity of orphanin receptor mRNA in the striatum is in
marked contrast to µ, d, and k receptor binding and mRNA
distribution in this region (Mansour et al., 1987, 1993,
1994a,b,c,d, 1995a,b, 1996). Providing further support for
a distinct divergence of the ORL1 and opioid receptor
systems, antisera directed against the µ and ORL1 recep-
tors have been shown to label different fibers in areas
involved in pain processing in the rat (Monteillet-Agius et
al., 1998).
The endogenous ligand for the ORL1 receptor binds with
high affinity and inhibits forskolin-stimulated cAMP accu-
mulation in stably transfected cells (Meunier et al., 1995;
Reinscheid et al., 1995; Saito et al., 1995, 1996, 1997;
Civelli et al., 1997). This heptadecapeptide, known as
orphanin FQ (OFQ), has a Gly-Gly-Phe motif in amino acid
positions 2–4 and an Asn-Gln sequence at the C terminus
which are identical to dynorphin A1–17, and several posi-
tively charged amino acids in the intervening sequence
(Meunier et al., 1995; Reinscheid et al., 1995). Orphanin
FQ demonstrates specific binding with the ORL1 receptor
(Dooley and Houghten, 1996; Reinscheid et al., 1996;
Shimohigashi et al., 1996; Ardati et al., 1997; Butour et al.,
1997; Guerrini et al., 1997). Several OFQ fragments with
high affinity binding to the ORL1 receptor also have been
identified (Dooley et al., 1997). Binding of OFQ to the
ORL1 receptor has been shown to stimulate ORL1-induced
Ca21 and K1 conductance changes (Conner et al., 1996,
1997; Knoflach et al., 1996; Nicol et al., 1996; Vaughan and
Christie, 1996; Abdulla and Smith, 1997; Ikeda et al.,









10 dorsal motor nucleus of the vagal nerve
10n vagus nerve or its root
12 hypoglossal nucleus
12n root of the hypoglossal nerve
A1 A1 noradrenaline cells
A2 A2 noradrenaline cells
A5 A5 noradrenaline cells
A7 A7 noradrenaline cells
AAA anterior amygdaloid area
ac anterior commissure
Acb accumbens nucleus
AcbC accumbens nucleus, core
AcbSh accumbens nucleus, shell
ACo anterior cortical amygdaloid nucleus
AD anterodorsal thalamic nucleus
AH anterior hypothalamic area
AHi amygdalohippocampal area
AI agranular insular
AM anteromedial thalamic nucleus
Amb nucleus ambiguous
AMPO anterior medial preoptic nucleus
AOD anterior olfactory nucleus, dorsal
AOE anterior olfactory nucleus, external
AOL anterior olfactory nucleus, lateral
AOM anterior olfactory nucleus, medial
AOP anterior olfactory nucleus, posterior
AOV anterior olfactory nucleus, ventral
AP area postrema
APir amygdalopiriform transition area
APT anterior pretectal nucleus
APTD anterior pretectal nucleus, dorsal part
APTV anterior pretectal nucleus, ventral part
ar acoustic radiation
Arc arcuate nucleus
ATg anterior tegmental nucleus
AV anteroventral thalamic nucleus
AVDM anteroventral thalamic nucleus, dorsomedial part
AVVL anteroventral thalamic nucleus, ventrolateral part
AVPO anteroventral preoptic nucleus
B basal nucleus of Meynert
BAOT bed nucleus of the accessory olfactory tract
Bar Barrington’s Nucleus
bic brachium of the inferior colliculus
BIC nucleus of the brachium of the inferior colliculus
BL basolateral amygdaloid nucleus
BLA basolateral amygdaloid nucleus, anterior part
BLP basolateral amygdaloid nucleus, posterior part
BM basomedial amygdaloid nucleus
BMA basomedial amygdaloid nucleus, anterior part
BMP basomedial amygdaloid nucleus, posterior part
bsc brachium of the superior colliculus
BST bed nucleus of the stria terminalis
BSTi bed nucleus of the stria terminalis, intermediate division
BSTIA bed nucleus of the stria terminalis, intra-amygdaloid divi-
sion
BSTl bed nucleus of the stria terminalis, lateral division
BSTld bed nucleus of the stria terminalis, lateral division, dorsal
part
BSTlj bed nucleus of the stria terminalis, lateral division, juxta-
capsular part
BSTlp bed nucleus of the stria terminalis, lateral division, poste-
rior part
BSTlv bed nucleus of the stria terminalis, lateral division, ventral
part
BSTma bed nucleus of the stria terminalis, medial division, ante-
rior part
BSTmpl bed nucleus of the stria terminalis, medial division, postero-
lateral part
BSTmpm bed nucleus of the stria terminalis, medial division, postero-
medial part
BSTmv bed nucleus of the stria terminalis, medial division, ventral
part
BSTS bed nucleus of the stria terminalis, supracapsular part
BSTv bed nucleus of the stria terminalis, ventral division
C1 C1 adrenaline cells
C2 C2 adrenaline cells
C3 C3 adrenaline cells
CA1-CA3 fields CA1-CA3 of Ammon’s horn
CA1–3so fields CA1-CA3 of Ammon’s horn, stratum oriens
CA1–3sp fields CA1-CA3 of Ammon’s horn, stratum pyramidal
CA1–3sr fields CA1-CA3 of Ammon’s horn, stratum radiatum
CA3sl field CA3 of Ammon’s horn, stratum lucidum
cc corpus callosum
Ce central amygdaloid nucleus
CeCv central cervical nucleus
CeL central amygdaloid nucleus, lateral
CeM central amygdaloid nucleus, medial
Cg cingulate gyrus
CG central gray
CGD central gray, dorsal
CGPn pontine central gray
CI caudal interstitial nucleus of the medial longitudinal fas-
ciculus
cic commissure of the inferior colliculus
CIC central nucleus of the inferior colliculus
Cl claustrum
CL centrolateral thalamic nucleus
CLi(B8) caudal linear nucleus of the raphe
CM central medial thalamic nucleus
CnF cuneiform nucleus
cp cerebral peduncle, basal
CPO caudal periolivary nucleus
CPu caudate putamen (striatum)
csc commissure of the superior colliculus
ctg central tegmental tract
cu cuneate fasciculus
Cu cuneate nucleus
CxA cortex-amygdala transition zone
DA dorsal hypothalamic area
DC dorsal cochlear nucleus
DCIC dorsal cortex of the inferior colliculus
dcs dorsal corticospinal tract
DEn dorsal endopiriform nucleus
df dorsal fornix
DG dentate gyrus
DGgr dentate gyrus, granule cell layer
DGhi dentate gyrus, hilum
DGmo dentate gyrus, molecular layer
DGpo dentate gyrus, polymorph layer
DH dorsal horn of the spinal cord
Dk nucleus of Darkschewitsch
dlf dorsal longitudinal fasciculus
DLL dorsal nucleus of the lateral lemniscus
DM dorsomedial hypothalamic nucleus
DMSp5 dorsomedial spinal trigeminal nucleus
DMTg dorsomedial tegmental area
DP dorsal peduncular cortex
DPGi dorsal paragigantocellular nucleus
DpMe deep mesencephalic nucleus
DPO dorsal periolivary nucleus
DR(B6,B7) dorsal raphe
DRG dorsal root ganglion
DTg dorsal tegmental nucleus
ECIC external cortex of the inferior colliculus
ECu external cuneate nucleus
Ent entorhinal cortex
EP entopeduncular nucleus
EP1 external plexiform layer, olfactory bulb
EW Edinger-Westphal nucleus
f fornix
F nucleus of the fields of Forel
fr fasciculus retroflexus
Fr frontal cortex
g7 genu of the facial nerve
G gelatinosus thalamic nucleus
Gi gigantocellular reticular nucleus
GI granular insular cortex
GiA gigantocellular reticular nucleus, alpha
GiV gigantocellular reticular nucleus, ventral
Gl glomerular layer, olfactory bulb
GP globus pallidus




GrO granular cell layer, olfactory bulb
Hb Habenula
HDB nucleus of the horizontal limb of the diagonal band of Broca
I intercalated nuclei of the amygdala
IAD interanterodorsal thalamic nucleus
IAM interanteromedial thalamic nucleus
IC inferior colliculus
ICj islands of Calleja




ILL intermediate nucleus of the lateral lemniscus
IMD intermediodorsal thalamic nucleus
IML intermediolateral cell column
IMLF interstitial nucleus of the medial longitudinal fasciculus
IMM intermediomedial cell column
In intercalated nucleus of the medulla
InCo intercollicular nucleus
IntA interposed cerebellar nucleus, anterior part
IntDL interposed cerebellar nucleus, dorsolateral part
IntDM interposed cerebellar nucleus, dorsomedial part
IntP interposed cerebellar nucleus, posterior part
IO inferior olive
IOA inferior olive, medial subnucleus A
IOB inferior olive, medial subnucleus B
IOD inferior olive, dorsal
IODM inferior olive, dorsomedial
IOM inferior olive, medial
IOPr inferior olive, principal
IPAC interstitial nucleus of the posterior limb of the anterior
commissure
IPC interpeduncular nucleus, caudal
IPD interpeduncular nucleus, dorsal
IPL interpeduncular nucleus, lateral
IPl internal plexiform layer, olfactory bulbl
IPN interpeduncular nucleus
IPR interpeduncular nucleus, rostral
IRt intermediate reticular nucleus
KF Kolliker-Fuse nucleus
La lateral amygdaloid nucleus
LA lateroanterior hypothalamic nucleus
Lat lateral (dentate) cerebellar nucleus
LatC lateral cervical nucleus
LatPC lateral cerebellar nucleus, parvicellular part
LC locus coeruleus
Ld lambdoid septal zone
LD laterodorsal thalamic nucleus
LDDM laterodorsal thalamic nucleus, dorsomedial part
LDVL laterodorsal thalamic nucleus, ventrolateral part
LDTg laterodorsal tegmental nucleus
lfp longitudinal fasciculus of the pons
lfu lateral funiculus of the spinal cord
LGN lateral geniculate nucleus
LH lateral hypothalamic area
LHb lateral habenula
ll lateral lemniscus
LM lateral mammillary nucleus
LO lateral orbital cortex
lo lateral olfactory tract
LOT nucleus of the lateral olfactory tract
LP lateral posterior thalamic nucleus
LPB lateral parabrachial nucleus
LPGi lateral paragigantocellular nucleus
LPO lateral preoptic area
LRt lateral reticular nucleus
LS lateral septal nucleus
LSD lateral septal nucleus, dorsal
LSI lateral septal nucleus, intermediate
LSO lateral superior olive
LSp lateral spinal nucleus
LSV lateral septal nucleus, ventral
LVe lateral vestibular nucleus
LVPO lateroventral periolivary nucleus
MA3 medial accessory oculomotor nucleus
MCPC magnocellular nucleus of the posterior commissure
MCPO magnocellular preoptic nucleus
MD mediodorsal thalamic nucleus
MDC mediodorsal thalamic nucleus, central part
MDL mediodorsal thalamic nucleus, lateral part
MDM mediodorsal thalamic nucleus, medial part
MdD medullary reticular nucleus, dorsal
MdV medullary reticular nucleus, ventral
Me medial amygdaloid nucleus
ME medial eminence
Me5 mesencephalic trigeminal nucleus
MeAD medial amygdaloid nucleus, anterodorsal
MeAV medial amygdaloid nucleus, anteroventral
Med medial (fastigial) cerebellar nucleus
MedDL medial cerebellar nucleus, dorsolateral protuberance
MePD medial amygdaloid nucleus, posterodorsal
MePV medial amygdaloid nucleus, posteroventral
MGN medial geniculate nucleus
MHb medial habenula
Mi mitral cell layer, olfactory bulb
MiTg microcellular tegmental nucleus
ml medial lemniscus
ML medial mammillary nucleus, lateral part
mlf medial longitudinal fasciculus
MM medial mammillary nucleus, medial part
MMn medial mammillary nucleus, median part
MnA median accessory nucleus of the medulla
MnPO median preoptic nucleus
MnR (Bmedian raphe nucleus5)
MO medial orbital cortex
Mo5 motor trigeminal nucleus
mp mammillary peduncle
MPA medial preoptic area
MPB medial parabrachial nucleus
MPO medial preoptic nucleus
MPOC medial preoptic nucleus, central part
MPT medial pretectal nucleus
MS medial septal nucleus
MSO medial superior olive
mt mammillothalamic tract
MT medial terminal nucleus of the accessory optic tract
MTu medial tuberal nucleus
MVe medial vestibular nucleus
MVeV medial vestibular nucleus, ventral
MVPO medioventral periolivary nucleus
Oc occipital cortex
opt optic tract
OPT olivary pretectal nucleus
OT nucleus of the optic tract




Pa paraventricular hypothalamic nucleus
PaAM paraventricular hypothalamic nucleus, anterior magnocel-
lular part
PaAP paraventricular hypothalamic nucleus, anterior parvicellu-
lar part
PaDC paraventricular hypothalamic nucleus, dorsal cap
PaLM paraventricular hypothalamic nucleus, lateral magnocellu-
lar part
PaMP paraventricular hypothalamic nucleus, medial parvicellular
part
PaPo paraventricular hypothalamic nucleus, posterior part
Par parietal cortex
PaS parasubiculum
PaV paraventricular hypothalamic nucleus, ventral part
PBG parabigeminal nucleus
PBP parabrachial pigmented nucleus
pc posterior commissure
PC paracentral thalamic nucleus
PCom nucleus of the posterior commissure
PCRt parvicellular reticular nucleus
PDTg posterodorsal tegmental nucleus
Pe periventricular hypothalamic nucleus
PeF perifornical nucleus
PF parafascicular thalamic nucleus
PH posterior hypothalamus
Pin pineal gland
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1997; Vaughan et al., 1997; Yu et al., 1997; Wagner et al.,
1998), protein kinase C activation (Lou et al., 1997), and to
effect the function of other neurotransmitter systems
(Faber et al., 1996; Giuliani and Maggi, 1996; Murphy et
al., 1996; Wang et al., 1996; Gintzler et al. 1997; Liebel et
al., 1997; Inoue et al., 1998; Konya et al., 1998). Intraven-
tricular injection of OFQ fails to produce cross-tolerance
with morphine (Hao et al., 1997) or conditioned place
preference (Devine et al., 1996a), but it has been impli-
cated in various modulatory effects of allodynia (Hara et
al., 1997; Minami et al., 1997) and nociception (Grisel et





PLCo posterolateral cortical amygdaloid nucleus
PLd paralambdoid septal nucleus
PLi posterior limitans thalamic nucleus
PMCo posteromedial cortical amygdaloid nucleus
PMD premammillary nucleus, dorsal
PMR paramedian raphe nucleus
PMV premammillary nucleus, ventral
Pn pontine nuclei
PN paranigral nucleus
PnC pontine reticular nucleus, caudal
PnO pontine reticular nucleus, oral
PnR pontine raphe nucleus
PnV pontine reticular nucleus, ventral
Po posterior thalamic nucleus group
PP peripeduncular nucleus
PPT posterior pretectal nucleus
PPTg pedunculopontine tegmental nucleus
PR prerubral field
Pr5 principal sensory trigeminal nucleus
PrC precommissural nucleus
Pr prepositus hypoglossal nucleus
PrS presubiculum
PT paratenial nucleus
PV paraventricular thalamic nucleus
PVA paraventricular thalamic nucleus, anterior





Re reuniens thalamic nucleus
ReIC recess of the inferior colliculus
Rh rhomboid thalamic nucleus
RI rostral interstitial nucleus of the medial longitudinal fas-
ciculus
RLi rostral linear nucleus of the raphe
RMC red nucleus, magnocellular
RMg(B3) raphe magnus nucleus
RN red nucleus
ROb (Braphe obscurus nucleus2)
RPa (Braphe pallidus nucleus1)
RPC red nucleus, parvicellular




RSA retrosplenial agranular cortex
RSG retrosplenial granular cortex
Rt reticular thalamic nucleus
RtTg reticulotegmental nucleus of the pons
RVL rostroventriculolateral reticular nucleus
S subiculum
s5 sensory root of the trigeminal nerve
SC superior colliculus
SC(DpG) superior colliculus, deep gray layer)
SC(DpWh) superior colliculus, deep white layer
SC(InG) superior colliculus, intermediate gray layer
SC(InWh) superior colliculus, intermediate white layer
SC(Op) superior colliculus, optic nerve layer
SC(SuG) superior colliculus, superficial gray layer)
SC(Zo) superior colliculus, zonal layer
SCh suprachiasmatic area









SNC substantia nigra, pars compacta
SNL substantia nigra, pars lateralis
SNR substantia nigra, pars reticulata
SO supraoptic nucleus
sol solitary tract
Sol nucleus of the solitary tract
SolC nucleus of the solitary tract, commissural
SolL nucleus of the solitary tract, lateral
SolM nucleus of the solitary tract, medial
SOR supraoptic nucleus, retrochiasmatic (diffuse)
sp5 spinal trigeminal tract
Sp5C spinal trigeminal nucleus, caudal
Sp5I spinal trigeminal nucleus, interpolar
Sp5O spinal trigeminal nucleus, oral
SPFPC subparafascicular thalamic nucleus, parvicellular
SPO superior paraolivary nucleus
SPTg subpeduncular tegmental nucleus
SpVe spinal vestibular nucleus
st stria terminalis
STh subthalamic nucleus














Tz nucleus of the trapezoid body
VCA ventral cochlear nucleus, anterior
VCP ventral cochlear nucleus, posterior
VDB nucleus of the vertical limb of the diagonal band of Broca
VEn ventral endopiriform nucleus
vfu ventral funiculus of the spinal cord
VH ventral horn of the spinal cord
VL ventrolateral thalamic nucleus
VLL ventral nucleus of the lateral lemniscus
VLTg ventrolateral tegmental nucleus
VM ventromedial thalamic nucleus
VMH ventromedial hypothalamic nucleus
VMHC ventromedial hypothalamic nucleus, central part
VMHDM ventromedial hypothalamic nucleus, dorsomedial part
VMHVL ventromedial hypothalamic nucleus, ventrolateral part
VO ventral orbital cortex
VP ventral pallidum
VPL ventral posterolateral thalamic nucleus
VPM ventral posteromedial thalamic nucleus
VTA ventral tegmental area
VTg ventral tegmental nucleus
X lamina 10 of the spinal cord
ZI zona incerta
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al., 1996; Xu et al., 1996; Dawson-Basoa and Gintzler,
1997; Heinricher et al., 1997; King et al., 1997; Liebel et
al., 1997; Morgan et al. 1997; Nishi et al., 1997; Tian et al.,
1997a,b; Yamamoto et al., 1997; Zhu et al., 1997), enticing
many to refer to this molecule as nociceptin. Subsequently,
OFQ also has been implicated in many other physiologic
and behavioral processes, including pituitary function
(Bryant et al., 1998; Doi et al., 1998), cardiovascular
control (Champion and Kadowitz, 1997a,b; Champion et
al., 1997; Gumusel et al., 1997; Chu et al., 1998), sodium
balance (Kapusta et al., 1997), feeding (Pomonis et al.,
1996; Stratford et al., 1997), learning (Sandin et al., 1997),
locomotion (Devine et al., 1996b; Florin et al., 1996,
1997a), stress response (Jenck et al., 1997), and sexual
behavior (Sinchak et al., 1997).
Orphanin FQ is derived from a larger precursor, and is
flanked by Lys-Arg proteolytic cleavage sites, similar to
dynorphin A1–17 (Mollereau et al., 1996b; Houtani et al.,
1996; Nothacker at al., 1996; Pan et al., 1996). The
precursor, also known as prepro-orphanin, contains two
other neuropeptides that may be biologically active; a
35-amino acid peptide upstream of the orphanin FQ
peptide, and a second 17-amino acid sequence immediately
downstream. Interestingly, this 17-amino acid sequence,
presently referred to as orphanin FQ2, has demonstrated
analgesic activity in high doses in mice (Rossi et al., 1998).
Prepro-orphanin closely shares structural homology to the
opioid peptide precursors prodynorphin and preproen-
kephalin, and it has been suggested recently that a
coordinated mechanism of evolution has separated
the orphanin FQ and opioid systems (Reinscheid et al.,
1998).
Given the potential physiological significance of the
orphanin system, elucidating the distribution of OFQ and
the ORL1 receptor within the CNS is critical to identify
specific neuroanatomic systems which may be influenced
by orphanin FQ. A detailed analysis of the distribution of
OFQ peptide immunoreactivity and prepro-orphanin
mRNA expression in the CNS of the rat has been reported
recently (Neal et al., 1999). Additionally, the distribution of
ORL1 receptor immunoreactivity in the rat CNS has been
reported in detail (Anton et al., 1996), as have general
descriptions of OFQ-stimulated GTPgS binding in the rat
and guinea pig brain (Sim et al., 1996; Sim and Childers,
1997), [3H]orphanin receptor binding in the mouse (Florin
et al., 1997b), 125I-labeled orphanin binding in the rat and
human hypothalamus (Makman et al., 1997), and pre-
proOFQ and ORL1 mRNA distribution in the developing
mouse brain (Ikeda et al., 1998). However, no detailed
analysis of receptor binding or expression of mRNA encod-
ing the ORL1 receptor throughout the rat CNS has been
reported to date. The present study was carried out to
characterize the detailed distribution of ORL1 mRNA
expression and orphanin FQ binding sites in the adult rat.
A 14Tyrosine substitute analog of the orphanin peptide was
125I-labeled by using the chloramine T method (Hunter and
Greenwood, 1962). By using this 125I-[14Tyr]-OFQ peptide
as a ligand, receptor autoradiographic methods were used
to visualize orphanin FQ receptor binding sites through-
out the rat CNS. In addition, by using a 35S-UTP– and
35S-CTP–labeled cRNA riboprobe to the ORL1 receptor, in
situ hybridization techniques were used to visualize ORL1
mRNA-expressing neurons in these same tissues.
MATERIALS AND METHODS
Animals
Adult male Sprague-Dawley rats (Charles River, Wil-
mington, MA; 250–300 g) were used for all in situ and
autoradiography studies. Handling and use of all animals
strictly conformed to NIH guidelines. Additionally, the
university unit for lab animal medicine (ULAM) at the
University of Michigan Medical Center approved protocols
for animal use in this study.
Tissue preparation
For in situ hybridization and autoradiography, adult
male Sprague-Dawley rats were killed by decapitation and
their brains and spinal cords were removed and immedi-
ately frozen in isopentane at 230°C. In addition to whole
brains, at the time of killing, pituitaries were also removed
and frozen in Lipshaw M-1 embedding matrix on powdered
dry ice. Brain, spinal cord, and pituitary tissue were stored
at 280°C until sectioning. All CNS material was sec-
tioned coronally on a Bright cryostat at 15 µm and thaw
mounted on polylysine-subbed microscope slides, then
stored at 280°C until used. Adjacent brain and pituitary
sections were used for in situ hybridization and receptor
autoradiography.
Iodination
An orphanin FQ peptide analog was synthesized with
the leucine residue in position 14 substituted with a
tyrosine for subsequent iodination (14Tyr-OFQ). The 125I-
[14Tyr]-OFQ peptide was labeled by the chloramine T
method (Hunter and Greenwood, 1962) and purified by
reverse-phase high performance liquid chromatography.
The monoiodinated species was obtained as a single peak
with an estimated specific activity of 2,200 Ci/mmol on the
day of iodination. The 125I-[14Tyr]-OFQ radioligand was
then stored in its elution buffer at 220°C until used for
receptor binding studies. Recent binding analyses have
demonstrated that 125I-[14Tyr]-OFQ exhibits identical bind-
ing characteristics at the ORL1 receptor as [3H]OFQ,
making this a suitable radioligand for pharmacologic
analysis of the ORL1 receptor by using in vitro assays
(Ardati et al., 1997).
Receptor autoradiography
Before incubation with the iodinated orphanin FQ pep-
tide, brain, spinal cord, and pituitary sections were brought
to room temperature (22°C) and placed in incubation
chambers to maintain ambient temperature and humidity
(60–80%). The incubation buffer consisted of the 125I-[14Tyr]-
OFQ peptide, 50 mM Tris (pH 5 7.0, 22°C), 1 mM
ethylenediaminetetraacetic acid, 0.1% bovine serum albu-
min, and protease inhibitor (0.1 mM phenylmethylsulfonyl
fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml
pepstatin, and 1 mM iodoacetamide). Incubation was
terminated by four consecutive washes, four minutes each,
in 50 mM Tris (pH 5 7.0, 0°C), followed by a distilled water
rinse. Scatchard analysis suggested a 0.1 nM Kd for the
125I-[14Tyr]-OFQ peptide. Therefore, a concentration of 0.1–
0.13 nM, which corresponds to a 50% receptor occupancy,
was chosen as a labeling concentration for the competition
and anatomic mapping studies.
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Upon completion of tissue treatment with the 125I-[14Tyr]-
OFQ ligand, brain and pituitary sections used for receptor
autoradiography were apposed to Kodak XAR-5 X-ray film
for 1–3 days, then subsequently dipped in NTB2 liquid
emulsion (Herkenham and Pert, 1982). Before emulsion
dipping, sections were exposed to paraformaldehyde va-
pors at 80°C for 2 hours in an evacuated desiccator. Lipids
were then removed by a series of ethanol washes (70–
100%), five xylene washes, a second series of ethanol
washes (100–70%), followed by distilled water rinse. The
slides were then dipped in emulsion, sealed in light-tight
boxes, and developed three days later.
Emulsion dipped sections were Nissl counterstained
with cresyl violet, dehydrated in graded alcohols followed
by xylene, and cover-slipped with Permount. Tissue sec-
tions were analyzed by using a ‘‘Dark-Lite’’ darkfield
stage-light on a Leitz DM RD microscope with camera
attachment. Representative sections were photographed
and images from negatives were generated on high quality
Kodak Photographic Paper for illustrations. All processing
was done under identical darkroom conditions.
Receptor autoradiography controls
Competition studies were performed on slide-mounted
forebrain and midbrain sections. Each brain section was
incubated with 200 µl of 125I-[14Tyr]-OFQ peptide in incuba-
tion buffer for 60 minutes at 22°C, and a minimum of eight
competing ligand concentrations were examined (0.03
nM – 10 µM). Nonspecific binding was evaluated by
treating adjacent brain sections with the same concentra-
tion of 125I-[14Tyr]-OFQ peptide and a 1 µM final concentra-
tion of unlabeled native orphanin FQ peptide. To pharma-
cologically characterize ORL1 receptor binding sites, a
series of µ (morphine, naloxone), d (DADL, DPDPE), and k
(bremazocine, U69,593) agonists were evaluated. In addi-
tion, the affinity of b-endorphin and OFQ peptide was
examined. Receptor binding was quantified by liquid scin-
tillation spectrophotometry.
cRNA probe
Hybridization of CNS tissue was performed by using a
35S-UTP and 35S-CTP-labeled riboprobe generated to the 58
region of the rat ORL1 receptor. The cRNA riboprobe was
generated from a 700-base cDNA that extended from the 58
UT region to 611 bases within the protein coding region of
the ORL1 receptor (Bunzow et al., 1994; Chen et al., 1994;
Mollereau et al., 1994; Fukuda et al., 1994; Wick et al.,
1994; Wang et al., 1994; Lachowicz et al., 1994).
In situ hybridization
The in situ hybridization technique used in this study
has been described previously for detection of opioid
receptor mRNA (Mansour et al., 1993, 1994a,b,d) and
prepro-orphanin FQ mRNA (Neal et al., 1999) in the rat
CNS. Adjacent sections of frozen brain, spinal cord, and
pituitary were removed from 280°C storage and placed
into 4% paraformaldehyde for 60 minutes at room tempera-
ture. Sections were next given three five-minute rinses in a
solution of 300 mM sodium chloride and 30 mM sodium
citrate, pH 7.2 (23 standard saline citrate [SSC]), followed
by treatment with proteinase K (1 µg/ml in 100 mM Tris
and 50 mM ethylenediaminetetraacetic acid, pH 8.0) for 10
minutes at 37°C. Sections were rinsed once in water then
treated with 0.1 M triethanolamine containing acetic
anhydride diluted to 400:1 vol/vol, pH 8.0, for 10 minutes
at room temperature. Sections were rinsed again in water,
dehydrated in graded alcohols, and then air-dried.
Prepared tissue was hybridized with a 35S-UTP and
35S-CTP-labeled riboprobe generated to the rat ORL1
receptor as described above. The cRNA probe was diluted
by using a hybridization buffer composed of 75% for-
mamide, 10% dextran sulfate, 33 SSC, 0.1 mg/ml yeast
tRNA, 13 Denhardt’s, and 10 mM dithiothreitol in 50 mM
Na2 PO4 (pH 7.4). The activity of 35S-labeled cRNA used for
hybridization was in the range of 1–2 3 106 cpm/35 µl. For
hybridization, 35 µl of diluted probe was applied to tissue
sections and coverslips were placed to keep the hybridiza-
tion buffer in contact with tissue. Tissue sections were
then placed in sealed humidifying chambers containing
50% formamide and hybridized overnight in a VRW Scien-
tific 1535 incubator (Cornelius, OR) at 55°C.
On day 2, glass coverslips were removed and slides were
rinsed two times in 23 SSC for 5 minutes, then treated
with RNase A for 60 minutes at 37°C (200 µg/ml RNase A
and 0.5 M NaCl in 100 mM Tris, pH 8.0). After RNase A
treatment, sections were washed in 23 SSC for five
minutes, followed by 13 SSC for 5 minutes and 0.53 SSC
for five minutes, all at room temperature. The low salt
wash was completed with incubation in 0.13 SSC for 60
minutes at 65°C. Sections were then rinsed in water,
dehydrated through graded alcohols, and air-dried.
Upon completion of hybridization, slide-mounted sec-
tions were opposed to Kodak XAR-5 X-ray film for five
days, then dipped in NTB2 film emulsion. Brain sections
were then developed after a 57-day exposure to NTB2
emulsion. The exposure time was chosen to maximize the
detection of in situ hybridization grains, and was deter-
mined empirically by means of periodic development of
test slides of tissue sections dipped in the NTB2 emulsion.
After development of the NTB2 film emulsion, all slides
were rinsed in running water at room temperature for 30
minutes and Nissl counterstained with cresyl violet. Slides
were dehydrated in graded alcohols followed by xylene,
and cover-slipped with Permount. Hybridized tissue was
analyzed by using a ‘‘Dark-Lite’’ darkfield attachment on a
Leitz DM RD microscope with camera attachment. Repre-
sentative sections were photographed, and images from
negatives were generated on high-quality Kodak Photo-
graphic Paper for illustrations. As with autoradiography
images, all processing was done under identical darkroom
conditions.
In situ hybridization controls
Several controls were performed to test the specificity of
the in situ hybridization results. First, in situ hybridiza-
tion studies were performed with a cRNA probe generated
to a different region of the rat ORL1 receptor (transmem-
brane regions III–VI) to determine whether the results
obtained were the same as with the more 58-derived cRNA
probe. Second, after 60 minutes in 4% paraformaldehyde,
sections from representative brain regions were incubated
in RNase A for 60 minutes at 37°C (200 µg/ml RNase A and
0.5 M NaCl in 100 mM Tris, pH 8.0) before treatment with
proteinase K. They were then run through the entire
hybridization procedure with 35S-labeled cRNA as de-
scribed above. Third, a separate set of adjacent, represen-
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tative brain regions were run through the entire hybridiza-
tion procedure as described above with the exception that
a 35S-labeled mRNA (sense strand) was used for the
hybridization. Other than the alterations described above
(RNase A and sense controls), all control tissues were
treated identically, and run along side adjacent sections
under normal conditions for comparison.
RESULTS
In situ hybridization controls
In situ hybridization that used two cRNA probes gener-
ated against different regions of the orphanin FQ receptor
produced the same mRNA localization at all levels of the
neuroaxis. Compare, for example, the in situ hybridization
image generated by using a cRNA directed against the
58UT, including 611 bases in the protein coding region (Fig.
1A), to that produced with a cRNA probe directed to
transmembrane 3–6 of the orphanin FQ receptor (Fig. 1C).
The ORL1 receptor mRNA distributions are indistinguish-
able, regardless of the cRNA probe used. In the remaining
figures, the 58UT cRNA probe was used for comparisons to
orphanin FQ receptor binding. Virtually no mRNA-
expressing cells were detected in tissues hybridized with a
35S-labeled mRNA (sense strand) directed to the 58UT or
the transmembrane 3–6 portion of the ORL1 cDNA se-
quence. Messenger RNA levels in these tissues were
negligible in all levels of the brain and spinal cord, with the
only exceptions being the cerebellar lobules and area CA1
of Ammon’s horn, where labeling was nonspecific and
unreliable (Fig. 1A,B). In addition, no mRNA expression
was detected in tissues pretreated with RNase A before in
situ hybridization by using 35S-labeled cRNA directed to
the 58UT or the transmembrane 3–6 portion of the ORL1
cDNA sequence. Similar to the sense strand control, these
tissues contained no mRNA-expressing cells at all levels
studied (Fig. 1C,D). Taken together, the results suggest
that the mRNA distribution that follows represents spe-
cific hybridization to orphanin FQ receptor mRNA.
Pharmacologic characterization
of receptor binding
Under the receptor autoradiographic conditions used in
the present study, only OFQ(1–17) peptide had high affinity
(IC50 5 0.39 nM) for the orphanin receptor binding site
(Table 1). Specific binding by 125I-[14Tyr]-OFQ represents
greater than 85% of total binding, as measured by liquid
scintillation spectrophotometry (Fig. 2). Prototypical µ
(morphine), d (DPDPE, DADLE), or k (bremazocine,
U69,593) agonists failed to compete for the orphanin
receptor sites, even at a 10 µM concentration. Similarly,
the opiate antagonist naloxone and the endogenous pep-
tide b-endorphin(1–31), failed to displace OFQ binding,
suggesting that the orphanin peptide is not labeling a
classic opioid binding site. These findings are consistent
with homogenate binding studies by using 125I-[14Tyr]-
OFQ (Ardati et al., 1997) and suggest that this ligand
selectively labels ORL1 binding sites under the autoradio-
graphic conditions used in this study.
In situ hybridization controls and OFQ binding data
demonstrated high specificity of the 35S-labeled ORL1
receptor riboprobes and 125I-[14Tyr]-OFQ peptide used in
this study. Results demonstrate that the orphanin FQ
receptor is diffusely distributed throughout the rat brain
and spinal cord. Orphanin receptor binding and mRNA
distributions vary markedly from previously reported µ, d,
and k receptor localization (Mansour et al., 1995b), suggest-
ing the labeling of a unique mRNA and binding site. The
anatomic distribution that follows is qualitative and de-
signed to provide an overview of the distribution of ORL1
mRNA (Figs. 3–5) and the orphanin FQ binding sites (Figs.
6–10) in the brain and spinal cord. Anatomic descriptions
and nomenclature primarily are based on those described
for the rat CNS by Paxinos and Watson (1997). Descriptive
anatomy of some CNS structures relies on previous nomen-
clature (Paxinos and Watson, 1986), particularly the neo-
cortex and several ventral mesencephalic structures. Such
areas are noted in the descriptive text. A detailed sum-
mary of the distribution of ORL1 mRNA and 125I-[14Tyr]-
OFQ binding throughout the rat CNS is also provided
(Table 2).
Cortex
In situ hybridization. Orphanin FQ receptor mRNA
expression is very dense in the neocortex throughout its
rostral to caudal extent. Cells containing ORL1 mRNA are
dense in layers II, IV, and VI, most numerous in layer IV.
Based on neocortical nomenclature by Paxinos and Watson
(1986), mRNA expression is slightly decreased in the
parietal and temporal cortices, compared with high expres-
sion levels in the frontal and occipital regions. In all
neocortical regions, mRNA expression is negligible to
sparse in layer V, and only slightly higher in layer II. No
mRNA expression is observed in layer I of the neocortex or
in the corpus callosum.
In other cortical regions, mRNA expression is also high.
Rostrally, the olfactory bulb contains low to sparse mRNA
expression in the mitral cell layer, extending into the
external anterior olfactory nucleus. No ORL1 message
expression is noted in other olfactory bulb layers. Moder-
ate mRNA expression is seen in the medial, lateral, and
ventral orbital cortices, highest in layer II. In general,
prefrontal cortical regions contain high mRNA expression.
Rostrally, ORL mRNA expression is low to moderate in the
infralimbic and dorsal peduncular cortical regions, persist-
ing into the ventral tenia tecta. Message expression in the
cingulate cortex is high and generally denser in area 1
than in areas 2 and 3. Cingulate ORL1-containing cells are
greatest in layers III and IV, slightly less in layer and II
and undetectable in layer I (Figs. 3A, 6D). This high
mRNA expression persists caudally into the retrosplenial
cortices, remaining high in layers II and IV of both the
granular and agranular parts (Figs. 3D, 6A). In the insular
cortex, mRNA expression is high in both the granular and
agranular parts, heaviest in layers II and IV. In the
piriform cortex, mRNA expression is generally dense. No
mRNA expression is observed in layer I, and only sparse
expression is seen in layer II. Moderate mRNA expression
in rostral layer III increases caudally to become high (Figs.
3A, 6B,D). In the entorhinal cortex, mRNA expression is
high in layers II, IV, V, and VI (Figs. 4B,C).
Orphanin FQ binding. Orphanin receptor binding is
robust throughout the neocortex, most dense in more
caudal regions. Binding is observed throughout the frontal
cortex, dense in layer IV, moderate in layer VI, and low in
the remaining layers. Labeling in the parietal cortex is
similar, but markedly diminished in layers IV and VI
(Figs. 6A,C, 7A). In the temporal cortex, orphanin binding
is the weakest of all neocortical regions, but still dense. No
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Fig. 1. Darkfield images of in situ hybridization controls.
A: Orphanin FQ receptor mRNA expression obtained after hybridiza-
tion with a 35S-labeled cRNA (antisense strand) generated against the
58UT portion of the ORL1 sequence. B: Labeling is absent in an
adjacent section hybridized with a 35S-labeled mRNA (sense strand)
generated against the same region of the orphanin receptor. Note
nonspecific labeling in area CA1 of Ammon’s horn. C: Orphanin FQ
receptor mRNA expression obtained after hybridization with a 35S-
labeled riboprobe generated against the transmembrane 3–6 region of
the ORL1 sequence. D: Labeling is absent in an adjacent section
treated with RNase A before in situ hybridization. For abbreviations,
see list. Scale bar 5 500 µm in D (applies to A–D).
labeling is observed in layer I, and moderate binding is
seen in layers II, III, and IV (Fig. 8A,C). Binding in
temporal layers V and VI is moderate and becomes dense
in the occipital cortex. Orphanin binding in the occipital
cortex is low to moderate in layers I–IV, and dense in
layers V and VI, persisting to the occipital pole (Fig. 8C).
No binding is observed in the corpus callosum.
In other cortical regions, the rostral olfactory bulb
contains dense binding in the glomerular layer, with
binding low to moderate in the mitral cell layer. Orphanin
binding is negligible in the remainder of the olfactory bulb.
Moderate binding is observed in the medial, lateral, and
ventral orbital cortices, primarily in superficial layers. In
the prefrontal cortical region, moderate binding is ob-
served in the infralimbic and dorsal peduncular cortices,
densest in layers V and VI. The adjacent ventral tenia
tecta contains only sparse labeling in layers I and III, with
no binding in layer II. Orphanin binding in the cingulate
cortex is the densest of all cortical regions (Figs. 6A,C, 7A).
Dense binding is observed in deeper layers and densest in
cingulate area 1. This pattern persists caudally, slightly
increasing into the retrosplenial cortices, where dense
binding is observed in the deeper layers of both the
granular and agranular parts (Fig. 7C). In the piriform
cortex, orphanin binding is negligible in layer I, moderate
in layer II, and dense in layer III, persisting to its caudal
extent (Fig. 6A). Binding in the agranular and granular
insular cortex is moderate to dense, densest in layers II,
III, and VI. In the entorhinal cortex, orphanin binding is
low in layers I and IV and moderate in layers V and VI
(Fig. 8A,C).
Ventral forebrain
In situ hybridization. Orphanin FQ receptor mRNA
expression is generally low throughout the ventral fore-
brain region. Rostrally, ORL1 mRNA expression is sparse
in the external anterior olfactory nucleus, and remains low
in the medial ventral and lateral parts. Message expres-
sion becomes moderate in its dorsal part, and this pattern
persists to its caudal extent. The posterior division con-
tains low mRNA expression. There are no mRNA-contain-
ing neurons observed in the rostral pole of nucleus accum-
bens. As accumbens differentiates into core and shell
components, scattered neurons with sparse mRNA expres-
sion are observed in the accumbens shell throughout its
rostral to caudal extent, with fewer mRNA-containing
neurons in accumbens core (Fig. 6B). The olfactory tu-
bercle contains no mRNA expression in layer I, sparse
labeling in the pyramidal layer (layer II) and low labeling
scattered throughout the polymorph layer (layer III).
Medial to the accumbens shell, the islands of Calleja,
including the major island, are devoid of mRNA expres-
sion. At the level of the diagonal band, mRNA-expressing
cells extending from the medial septum are lightly scat-
tered in the ventral diagonal band and ventral pallidum
(Fig. 3A). Caudally, a moderate number of ORL1-contain-
ing neurons are observed in the horizontal diagonal band
(Fig. 3A,B). Messenger RNA expression is sparse to low in
the interstitial nucleus of the posterior limb of the anterior
commissure, and the substantia innominata.
Orphanin FQ binding. In contrast to ORL1 mRNA
expression, orphanin binding is quite dense throughout
the ventral forebrain. Throughout the anterior olfactory
nucleus OFQ binding is dense. Rostrally, binding is dense
in the external division, mostly in its dorsal part. Through-
out the remainder of the nucleus, binding is dense in the
ventral division, moderate in the dorsal and lateral divi-
sions, and low to moderate in the posterior division. At the
emergence of nucleus accumbens, the olfactory tubercle
contains moderate to dense binding, primarily in the
plexiform layer (Fig. 6A,C). No binding is observed in the
islands of Calleja. At the level of the rostral nucleus
accumbens, low binding is observed in small patches in the
accumbens core, persisting throughout (Fig. 6A). In the
accumbens shell, binding increases slightly, becoming
moderate at caudal levels. Just caudal to nucleus accum-
bens, binding becomes moderate, filling the interstitial
nucleus of the posterior limb of the anterior commissure.
Low binding is observed throughout the vertical limb of
the diagonal band, with moderate binding in the horizon-
tal limb of the diagonal band. The substantia innominata
contains negligible binding rostrally, adjacent to the hori-
zontal diagonal band, and dense binding further caudal at
the level of the amygdala.
Septum
In situ hybridization. Orphanin receptor mRNA ex-
pression in this region is moderate to dense. Rostrally,
moderate expression is observed in the intermediate lat-
eral septum, with moderate to dense mRNA expression in
its ventral part (Figs. 3A,B, 6D). At this level, mRNA
expression extends medially from the intermediate and
dorsal lateral septum into the septohippocampal nucleus,
where it becomes high. The dorsal lateral septum contains
moderate mRNA expression throughout its rostral to
caudal extent. The medial septum contains a moderate
number of mRNA-expressing neurons, with low expres-
sion in the adjacent lambdoid septal zone and sparse,
scattered mRNA-expressing neurons in the paralambdoid
septal nucleus. Caudal to the medial septum, the septofim-
brial nucleus and dorsal fornix are devoid of mRNA
expression. A population of ORL1-containing neurons in
the caudal part of the ventral lateral septal nucleus
extends ventromedially to the crossing of the anterior
commissure. This ventromedial cell group (previously de-
scribed as the septohypothalamic nucleus by Paxinos and
Watson, 1986) contains moderate mRNA expression.
Orphanin FQ binding. Similar to ORL1 mRNA ex-
pression, orphanin binding in the lateral septum is also
moderate. Adjacent to the caudal dorsal peduncular cor-
tex, the dorsal tenia tecta contains moderate binding. At
this rostral level, the ventral lateral septal nucleus con-
tains only sparse binding and the intermediate lateral
septum is devoid of binding. Further caudal, the septohip-
pocampal nucleus emerges with low binding, and binding









1Results of competition studies (IC50 nM) comparing affinity of several opioid compounds
to that of orphanin FQ peptide at the orphanin receptor. None of the opioid agonists or
antagonists tested were able to compete for the orphanin receptor binding site.
Prototypical µ (morphine), d (DPDPE, DADLE), or k (bremazocine, U69,593) agonists
failed to compete for the orphanin receptor sites, even at a 10 µM concentration.
Similarly, the opiate antagonist naloxone and the endogenous peptide b-endorphin
failed to displace binding. In contrast, orphanin FQ(1–17) peptide had high affinity
(IC50 5 0.39 nM) for the orphanin receptor binding site.
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Fig. 2. A: Darkfield image of orphanin FQ receptor binding ob-
tained in the rostral forebrain by using 125I-[14Tyr]-OFQ as the
radioligand. B: Addition of a saturating concentration of unlabeled
OFQ to the 125I-[14Tyr]-OFQ receptor binding assay generates negli-
gible nonspecific labeling. For abbreviations, see list. Scale bar 5 500
µm in B (applies to A,B).
in the dorsal lateral septal nucleus is moderate. At this
level, low to moderate binding is observed in the ventral
lateral septal nucleus, with sparse binding in the interme-
diate part (Fig. 6A,C). This pattern persists to the caudal
extent of the lateral septal complex. In the medial septum,
orphanin binding is also low, with only sparse binding in
the adjacent lambdoid nucleus, and no binding in the
paralambdoid nucleus. Low to moderate binding is ob-
served in the region of the septofimbrial nucleus. The
region corresponding to the septohypothalamic nucleus is
devoid of OFQ binding.
Basal ganglia
In situ hybridization. At the level of the caudal
anterior olfactory nucleus, the dorsal endopiriform nucleus
emerges with moderate ORL1 mRNA expression. This
pattern persists to the level of the preoptic region, where
mRNA expression is highest in both this nucleus and the
ventral endopiriform nucleus (Fig. 3A,B). High mRNA
expression persists in both nuclei to their caudal extent. In
the rostral forebrain, mRNA expression is low in the
claustrum, with ORL1-containing neurons scattered
throughout this structure at all levels. The striatum
contains even fewer mRNA-expressing cells, with negli-
gible to sparse mRNA expression throughout its extent
(Figs. 3A,B,C, 6B,D). Sporadic mRNA-containing neurons
that are observed in this structure are confined to the
dorsolateral part.
In marked contrast to the paucity of mRNA expression
in the striatum, large neurons with abundant mRNA
expression are scattered throughout the globus pallidus
(Fig. 3B). Although few to moderate in number, these
neurons are large and contain abundant mRNA signal
intensity. This expression pattern persists to the caudal
extent of the globus pallidus. Adjacent to the globus
pallidus, mRNA expression in the basal nucleus of Mey-
nert is moderate to high and in the entopeduncular
nucleus mRNA expression is low. In the caudal forebrain,
Fig. 3. A–F: Darkfield autoradiograms of orphanin FQ receptor mRNA distribution in representative
coronal sections through the forebrain. For abbreviations, see list. Scale bar 5 500 µm in F (applies to A–F).
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the subthalamic nucleus contains a moderate number of
ORL1-containing neurons. At this level, mRNA expression
is low to moderate in the substantia nigra, pars reticulata,
with large ORL1-containing neurons scattered throughout
this region (Fig. 8B). Messenger RNA expression increases
significantly in pars compacta, where numerous cells with
high mRNA expression are noted, most heavily in its
ventromedial aspects (Figs. 4A,B, 8D). In the dorsal pars
compacta, ORL1 expression abates somewhat, with low
mRNA expression observed in pars lateralis.
Orphanin FQ binding. At the emergence of the dorsal
endopiriform nucleus, dense orphanin binding is observed.
Receptor binding fills the nucleus and persists to its caudal
extent. The ventral endopiriform nucleus contains sparse
to low levels of binding throughout (Fig. 6A). The claus-
trum emerges adjacent to the dorsal endopiriform nucleus
in the rostral forebrain with dense binding that persists
throughout this structure. In contrast to the claustrum,
binding in the caudate-putamen is generally negligible,
except for occasional sparse patches of binding located
dorsomedially, adjacent to the lateral ventricle (Fig. 6A,C).
At the emergence of the globus pallidus moderate binding
is observed in a diffuse, reticular pattern throughout the
nucleus. At the level of the caudal globus pallidus, the
basal nucleus of Meynert and entopeduncular nucleus are
devoid of OFQ binding. In the caudal forebrain, there are
low levels of binding in the subthalamic nucleus. This
pattern persists caudally into the substantia nigra, pars
reticulata, where moderate to heavy OFQ binding is
observed in its rostral half (Fig. 8A). Orphanin binding
decreases to become sparse in the caudal part of pars
reticulata. Pars compacta contains moderate binding
throughout (Fig. 8C), extending into pars lateralis, where
orphanin binding is very low.
Basal telencephalon
In situ hybridization. At the level of the crossing of
the anterior commissure, high mRNA expression is ob-
served in the median preoptic nucleus (Fig. 3B). Orphanin
receptor-expressing cells extend from this nucleus ven-
trally into the periventricular hypothalamic nucleus, where
moderate mRNA expression is observed. Dense mRNA
expression is also observed ventrally in the anteromedial
preoptic nucleus. The anteroventral preoptic nucleus con-
tains a moderate number of mRNA-expressing neurons at
this level, extending into the adjacent horizontal limb of
the diagonal band. Within the medial preoptic area, mRNA
expression is moderate and diffuse, with more numerous
mRNA-expressing neurons in its ventral part. In the
lateral preoptic area, mRNA expression is moderate in its
more medial portion, and sparse to low laterally. Adjacent
to the horizontal diagonal band, the magnocellular preop-
tic nucleus contains scattered neurons with low mRNA
expression. Caudally, the medial preoptic nucleus contains
moderate mRNA expression, becoming dense in its ventral
part and sparse to low in its central part (Fig. 3B). At the
caudal boundary of the preoptic region, sparse to low
mRNA expression is observed in layers I and III of the
nucleus of the lateral olfactory tract. In contrast, high
mRNA expression is observed diffusely throughout layer II
of this nucleus, to its caudal extent.
The bed nucleus of the stria terminalis has a varied
mRNA expression pattern but is predominantly dense
(Fig. 3B). In the rostral pole of the bed nucleus, scattered
neurons are observed with sparse mRNA expression. At
this level, sparse expression is noted in the lateral division
and low mRNA expression in the ventral division. At the
level of the anterior commissure crossing, the anterior part
of the medial division contains low mRNA expression, with
a moderate number of mRNA-expressing cells observed in
the dorsal part of the lateral division. No mRNA expres-
sion is observed in the juxtacapsular part of the lateral
division, adjacent to the internal capsule. The ventral
division and ventral part of the lateral division contain
only scattered mRNA-expressing cells. At the level of the
rostral thalamus, mRNA expression becomes high, primar-
ily in the posterior parts of the medial and lateral divi-
sions. High mRNAexpression is observed in the posterome-
dial and posterolateral parts of the medial division and in
the posterior part of the lateral division.
Fig. 4. A–C: Darkfield autoradiograms of orphanin FQ receptor mRNA distribution in representative
coronal sections through the mesencephalon. For abbreviations, see list. Scale bar 5 500 µm in C (applies
to A–C).
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Orphanin FQ binding. Compared with ORL1 mRNA
expression, binding in the basal telencephalon is low. At
the emergence of the rostral preoptic region, OFQ binding
is negligible. At this level, the periventricular hypotha-
lamic nucleus is also devoid of binding. Labeling increases
in intensity caudally, becoming low to moderate in the
Fig. 5. A–C: Darkfield autoradiograms of or-
phanin FQ receptor mRNA distribution in repre-
sentative coronal sections at the level of the
metencephalon, myelencephalon and spinal cord,
including the dorsal root ganglion. For abbrevia-
tions, see list. Scale bar 5 500 µm in A (applies to
A–C).
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Fig. 6. Darkfield autoradiograms comparing 125I-[14Tyr]-OFQ binding (A,C) and orphanin receptor
mRNA expression (B,D) at representative levels of the rostral forebrain. For abbreviations, see list. Scale
bar 5 500 µm in D (applies to A–D).
Fig. 7. Darkfield autoradiograms comparing 125I-[14Tyr]-OFQ binding (A,C) and orphanin receptor
mRNA expression (B,D) at representative levels of the mid- and mid-caudal forebrain. For abbreviations,
see list. Scale bar 5 500 µm in D (applies to A–D).
578 C.R. NEAL JR. ET AL.
Fig. 8. Darkfield autoradiograms comparing 125I-[14Tyr]-OFQ binding (A,C) and orphanin receptor
mRNA expression (B,D) at representative levels of the midbrain. For abbreviations, see list. Scale bar 5
500 µm in D (applies to A–D).
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Fig. 9. Darkfield autoradiograms compar-
ing 125I-[14Tyr]-OFQ binding (A,C,E) and or-
phanin receptor mRNA expression (B,D,F)
at representative levels of the pons (A–D)
and mid-medulla (E, F). Note that, as dis-
cussed in the text, all mRNA expression and
OFQ binding shown in the cerebellar lobules
is nonspecific. For abbreviations, see list.
Scale bar 5 500 µm in F (applies to A–F).
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medial preoptic area proper, mostly in its ventral part. The
anteromedial preoptic nucleus contains only sparse bind-
ing rostrally, low to moderate caudally. Moderate binding
is observed throughout the anteroventral preoptic nucleus.
Orphanin binding in the median preoptic nucleus is dense
throughout, in both its dorsal supracommissural and
ventral parts. The lateral preoptic region contains diffuse,
low binding at all levels. In the caudal preoptic region,
binding remains low to moderate in the ventral medial
preoptic area, with negligible binding noted in the medial
preoptic nucleus. Binding in the magnocellular preoptic
nucleus is low. The nucleus of the lateral olfactory tract
contains dense binding. In contrast to the high mRNA
expression noted in layer II of this structure, binding is
dense in layer I and only low to moderate in layers II and
III.
Orphanin binding in the bed nucleus of the stria termi-
nalis is generally moderate. At the most rostral levels of
this region, only sparse OFQ binding is noted in the rostral
bed nucleus, persisting with only low levels of binding in
the adjacent anterior part of the medial division sparse
binding is observed in the ventral division. The septohypo-
thalamic nucleus at this level contains low levels of OFQ
binding. At the level of the anterior commissure crossing,
binding intensity increases in the lateral division of the
bed nucleus. Moderate binding is observed in the dorsal
and ventral parts of the lateral division. The juxtacapsular
part of the lateral division is devoid of binding. At the level
of the rostral thalamus, the posteromedial part of the
medial division and posterior part of the lateral division of
the bed nucleus of the stria terminalis are devoid of
binding, whereas the posterolateral and posterointermedi-
ate parts of the medial division contain moderate to dense
binding. This pattern persists to its caudal boundaries.
Hypothalamus
In situ hybridization. In the hypothalamic region, no
mRNA expression is observed in the median eminence.
The anterior pituitary, intermediate pituitary, and pineal
gland are also devoid of ORL1 mRNA expression. Ros-
trally, in the ventral part of the hypothalamus, numerous
ORL1-expressing neurons are observed in the supraoptic
nucleus (Figs. 3C, 7B). These neurons fill the nucleus
throughout its extent. At this level, the suprachiasmatic
nucleus contains low mRNA expression, with neurons
lightly scattered in a circumferential manner throughout
the nucleus. Expression is sparse in the retrochiasmatic
region. Further caudal, a sparse number of mRNA-
expressing cells is noted in the tuber cinereum, slightly
increased in the medial tuberal nucleus. At the emergence
of the arcuate nucleus, mRNA expression increases dra-
matically, becoming high throughout this nucleus. Al-
Fig. 10. Darkfield autoradiograms comparing 125I-[14Tyr]-OFQ binding (A,C) and orphanin receptor
mRNA expression (B,D) in the caudal medulla (A,B) and spinal cord with dorsal root ganglion (C,D). For
abbreviations, see list. Scale bar 5 500 µm in D (applies to A–D).
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TABLE 2. Distribution of ORL1 mRNA Expression and 125I-[14Tyr]-OFQ
Binding in the Central Nervous System of the Adult Male Rat1





Layer I 2 1
Layer II 111 1
Layer III 11 11
Layer IV 1111 1111
Layer V 1 11
Layer VI 111 111
Parietal
Layer I 2 1
Layer II 11 1
Layer III 11 11
Layer IV 111 111
Layer V 11 11
Layer VI 111 11
Temporal
Layer I 2 2
Layer II 111 11
Layer III 11 11
Layer IV 1111 1
Layer V 11 111
Layer VI 111 11
Occipital
Layer I 2 11
Layer II 111 1
Layer III 11 11
Layer IV 11111 11
Layer V 11 11111



















































































Layer I 11 11111
Layer II 1111 11
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TABLE 2. (continued)
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though mRNA expression is diffusely located throughout
the arcuate nucleus, ORL1-containing neurons are most
numerous ventromedially (Fig. 3D–F). The ventromedial
nucleus is the most densely labeled structure in the
hypothalamus, heavily labeled at all levels, with mRNA
expression slightly higher in the dorsomedial part than in
the ventrolateral part (Figs. 3D,E, 7D). At mid-caudal
levels, mRNA expression in the dorsomedial part of the
ventrolateral nucleus decreases laterally and is moderate
in the medial tuberal nucleus and tuber cinereum.
In the dorsal part of the hypothalamus, mRNA expres-
sion in the posterior bed nucleus of the stria terminalis
decreases and becomes low to moderate in the anterior and
lateral hypothalamic areas. There is a decrease in mRNA
levels in this transition area in the periventricular nucleus
also, with mRNA expression low to moderate. The paraven-
tricular nucleus demonstrates differential mRNA expres-
TABLE 2. (continued)






















































































































































1Degree of mRNA expression and OFQ binding were arbitrarily graded, based on
density and intensity of binding, and intensity of microscopic mRNA expression on
emulsion-dipped sections. Gradations used for mRNA expression are as follows: highest
signal intensity, 11111; high, 1111; moderate, 111; low to moderate, 11; low or
sparse, 1; undetectable, 2. Gradations used for OFQ binding are as follows: densest
signal intensity, 11111; dense, 1111; moderate, 111; low to moderate, 11; low or
sparse, 1; undetectable, 2. For abbreviations, see list.
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sion, with moderate expression in the anterior parvicellu-
lar part, and high expression in the ventral and lateral
magnocellular parts (Figs. 3C, 7B). Caudally in this
nucleus, mRNA-expressing neurons are lightly scattered
in the posterior part and dorsal cap. Caudal to the paraven-
tricular nucleus, mRNA expression is sparse in the dorsal
hypothalamic area and moderate in the dorsomedial hypo-
thalamic nucleus (Figs. 3D, 7D). Lateral to the dorsal
hypothalamic area, the perifornical nucleus contains sparse
expression, with moderate expression into the posterior
hypothalamus (Fig. 3E). There is only sparse to low mRNA
expression detected in the terete hypothalamic nucleus.
In the mammillary region, ORL1 mRNA expression in
the ventral premammillary nucleus is high but diffuse.
The adjacent dorsal premammillary and tuberal magnocel-
lular nuclei contain sparse mRNA expression. In the
rostral mammillary nuclear complex, the medial mammil-
lary nucleus is devoid of mRNA expression in its lateral
part. Lightly scattered mRNA-containing neurons are
observed in the rostral supramammillary nucleus, becom-
ing more moderate in number at caudal levels. The medial
part of the medial mammillary nucleus contains low to
moderate mRNA expression (Fig. 3F). The mammillary
peduncle and supramammillary decussation are devoid of
mRNA expression.
Orphanin FQ binding. Orphanin binding in the
hypothalamus has an overall similar distribution pattern
to that of ORL1 mRNA expression. As with mRNA expres-
sion, no binding is seen in the median eminence, the
anterior and intermediate pituitary, and the pineal gland.
In the rostral part of the hypothalamus, the suprachias-
matic nucleus contains dense binding, filling the nucleus
at all levels. Binding in the supraoptic nucleus is sparse to
low. The retrochiasmatic supraoptic nucleus is devoid of
binding. Binding in the retrochiasmatic area is diffuse and
low, with increased intensity into the arcuate region. The
rostral arcuate nucleus contains sparse orphanin binding
in its lateral region and low to moderate binding medially.
The density of binding sites increases slightly in more
caudal regions, but generally moderate in the arcuate (Fig.
7B). The tuber cinereum, medial tuberal nucleus, and
perifornical nucleus all contain moderate to dense OFQ
binding at all levels. As with mRNA expression, the
ventromedial nucleus shows the densest binding in the
hypothalamus (Fig. 7C). Rostrally, the shell region of this
structure shows moderate levels of binding that increases
caudally to become dense throughout the shell and core
regions, equally dense in the dorsomedial and ventrolat-
eral parts.
In the dorsal part of the hypothalamus, orphanin bind-
ing in the anterior and lateral hypothalamic regions is low
to moderate (Fig. 7A). Binding in the periventricular
nucleus rostrally is very sparse. Further caudal, the
paraventricular nucleus has low orphanin binding in the
parvicellular region (Fig. 7A). In the rostral pole of the
paraventricular nucleus, only sparse binding is observed
the anterior parvicellular part. Signal intensity increases
somewhat to become low to moderate in the lateral magno-
cellular and posterior parts, becoming moderate to dense
in the ventral part and dorsal cap. Caudal to the paraven-
tricular nucleus, the dorsal hypothalamic area is devoid of
binding. Binding in the dorsomedial hypothalamus is low
(Fig. 7C). Labeling in the posterior hypothalamus is low to
moderate. The terete hypothalamic nucleus contains dense
OFQ binding throughout its extent.
In the caudal hypothalamus, the tuberal magnocellular
nucleus is devoid of OFQ binding and binding in the
ventral premammillary nucleus only consists of occasional
sparse patches. The dorsal premammillary nucleus con-
tains low to moderate labeling at all levels, increasing in
density into the mammillary bodies. Orphanin FQ binding
in the lateral mammillary nucleus and median part of the
medial mammillary nucleus is negligible. This is in con-
trast to the supramammillary nucleus and lateral part of
the medial mammillary nucleus, where binding is moder-
ate to dense at all levels. No OFQ binding is observed in
the mammillary peduncle and supramammillary decussa-
tion.
Amygdala
In situ hybridization. Rostrally, mRNA-expressing
cells are sparsely scattered in the anterior amygdaloid
area and anterior cortical amygdala. Orphanin receptor
mRNA expression is low to moderate in the cortex-
amygdala transition zone. At the level of the paraventricu-
lar hypothalamus, low mRNA expression is observed in the
rostral medial and anterior cortical nuclei, with low to
moderate expression in the basolateral nucleus (Figs. 3C,
7A). The bed nucleus of the accessory olfactory tract
contains moderate to dense mRNA expression at this level.
The central nucleus contains an occasional mRNA-
containing neuron in its lateral part but is essentially
devoid of mRNA expression (Fig. 7B,D).
Further caudal, the anterodorsal division of the medial
nucleus contains low mRNA expression, with dense expres-
sion in the anteroventral division. At this level, the ante-
rior part of the basomedial nucleus contains moderate
mRNA expression, with low signal detected in the anterior
basolateral nucleus (Fig. 3D). In the most caudal part of
the medial nucleus, the posterodorsal division contains
low to moderate expression, whereas the posteroventral
division is filled with numerous densely labeled mRNA-
expressing cells (Figs. 3D, 7D). Moderate mRNA expres-
sion is observed extending into the basolateral and postero-
lateral cortical nuclei at this level. The basomedial nucleus
has moderate to dense mRNA expression, and only sparse
expression is observed in the lateral nucleus, in both the
ventral and dorsal divisions. The intercalated nuclei of the
amygdala contain scattered, sparse mRNA-expressing cells.
In the caudal amygdala, the posterior basomedial nucleus
and posterior basolateral nucleus contain low to moderate
mRNA expression at all levels. Scattered neurons with low
levels of mRNA expression are observed throughout the
posteromedial and posterolateral cortical amygdala nuclei
and the amygdalohippocampal area (Fig. 3E,F). The intra-
amygdaloid bed nucleus of the stria terminalis is devoid of
mRNAexpression. Transitioning into the ventral hippocam-
pal region, the amygdalopiriform transition area contains
moderate mRNA expression.
Orphanin FQ binding. In the rostral pole of the
amygdala, the ventral and dorsal parts of the anterior
amygdaloid area contains only sparse binding. This bind-
ing increases somewhat into the anterior cortical nucleus,
where low to moderate binding is observed. The cortex-
amygdala transition zone is devoid of orphanin binding.
Low to moderate binding is observed in the anterior part of
the medial and basolateral nuclei (Fig. 7A), with moderate
binding in the rostral bed nucleus of the accessory olfac-
tory tract. Further caudal, the anterodorsal division of the
medial nucleus emerges with moderate to dense binding
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(Fig. 7C). At this level, binding in the bed nucleus of the
accessory olfactory tract becomes dense. The anterior
cortical nucleus and dorsal lateral part of lateral nucleus
contain low to moderate binding, with sparse binding in
the anterior part of the basomedial and basolateral nuclei.
Only sparse binding is observed in the region of the
intercalated nuclei, and the central nucleus is devoid of
binding at all levels (Fig. 7C). The basolateral nucleus
contains moderate to dense binding in its anterior part,
sparse to low posteriorly.
In the caudal amygdala, no binding is observed in the
posterolateral cortical nucleus and basomedial nucleus.
The posteroventral division of the medial nucleus contains
dense binding, while binding in the posterodorsal region is
sparse to low. This pattern in the medial nucleus persists
until the most caudal level of the amygdala, where binding
is conspicuously absent in the caudal pole of the posterodor-
sal division of the medial nucleus. At this level, the
posteromedial cortical nucleus has moderate to dense
binding. Low to moderate binding is observed in the lateral
nucleus, in both the dorsolateral and ventromedial parts.
Binding in the intra-amygdaloid portion of the bed nucleus
of the stria terminalis is sparse, and the posterior basome-
dial nucleus is devoid of binding. In transition to the
ventral hippocampus, the amygdalohippocampal area con-
tains moderate to dense binding, whereas the amygdalopiri-
form transition shows no orphanin binding.
Hippocampal formation and related
structures
In situ hybridization. In the rostral forebrain, at the
level of the septal nuclei, the septohippocampal nucleus
contains high ORL1 mRNA expression. Dorsal to the
corpus callosum, only sparse mRNA expression is observed
in the indusium griseum. The subfornical organ contains
moderate to dense mRNA expression at all levels. The
fornix is devoid of mRNA expression. In the caudal fore-
brain, the subiculum contains moderate to dense mRNA
expression. These mRNA-expressing neurons are found in
both the dorsal and ventral components of the subiculum,
with message expression heaviest in deeper layers (Fig.
8D). Orphanin receptor mRNA expression is sparse in the
presubiculum and parasubiculum, at all levels.
Orphanin receptor mRNA expression in the hippocam-
pal formation is generally lower in rostral than in caudal
levels, with particularly increased expression in the ven-
tral part of the dentate gyrus and Ammon’s horn (Figs. 3,
4A,B, 7B,D, 8B). Rostrally, the hilus of the dentate gyrus
contains scattered, sparsely labeled neurons, with no
mRNA expression detected at more caudal levels. In the
polymorph layer of the dentate gyrus (also referred to as
area CA3c of Ammon’s horn), no mRNA expression is
observed rostrally, but low to moderate levels are observed
scattered in this layer in the caudal ventral region. The
molecular layer contains no mRNA expression at all levels.
The granule cell layer of the dentate gyrus has moderate to
high mRNA expression rostrally, with dense expression in
caudal ventral levels. This dense mRNA pattern persists to
its caudal extent.
In Ammon’s horn, area CA1 has sparse to negligible
mRNA expression rostrally, primarily in stratum pyrami-
dal. Stratum radiatum and oriens are devoid of labeling at
this level. Caudally, mRNA expression remains sparse to
negligible in stratum pyramidal, with only an occasional
scattered mRNA-expressing neuron observed in stratum
oriens and radiatum. This mRNA expression is also evi-
dent in area CA1 in sense control sections, and this sparse
labeling is most likely nonspecific. In area CA2, occasional
mRNA-expressing neurons are observed rostrally in stra-
tum pyramidal, with stratum radiatum and oriens devoid
of labeling. In caudal area CA2, stratum pyramidal con-
tains moderate to high mRNA expression, with lightly
scattered cells observed in stratum oriens and radiatum.
Area CA3 contains sparse mRNA expression in stratum
lucidum, oriens, and radiatum at rostral levels, with high
mRNA expression in stratum pyramidal. In caudal area
CA3, mRNA expression in stratum pyramidal becomes
dense, with no real change in stratum lucidum and
radiatum. Stratum oriens in caudal area CA3 shows
significant increase in signal intensity, with mRNA expres-
sion high at this level.
Orphanin FQ binding. At the level of the septal
nuclei, orphanin binding is low in both the subfornical
organ and the septohippocampal nucleus, moderate to
dense in the indusium griseum. The fornix is devoid of
orphanin binding at all levels. In the caudal forebrain, the
dorsal subiculum emerges with dense binding in all layers
(Fig. 8A). This binding pattern persists throughout the
dorsal and ventral subiculum (Fig. 8C). In contrast to
dense subiculum binding, orphanin binding in the presu-
biculum and parasubiculum is low.
In contrast to the rostral to caudal differences observed
with ORL1 mRNA expression, orphanin binding in the
hippocampal formation is generally unchanged from ros-
tral to caudal levels (Figs. 7A,C, 8A). No orphanin FQ
binding is observed in the dentate gyrus in the granule cell
layer, hilus, or polymorph layer. The molecular layer is
filled with moderate to dense binding, slightly denser in
the caudal ventral region than at more rostral levels. In
Ammon’s horn, area CA1 contains almost no orphanin
binding. Sparse, patchy binding is observed in caudal
stratum oriens, but no binding is observed in stratum
pyramidal or stratum oriens at all levels. Area CA2 of
Ammon’s horn has slightly more binding than area CA1.
Rostrally, sparse receptor binding is observed in stratum
oriens and stratum radiatum, with only a slight increase
in caudal levels in stratum oriens. No binding is observed
in stratum pyramidal at all levels. In area CA3, very dense
binding is observed in stratum oriens, with low to moder-
ate binding observed in stratum lucidum, primarily at
rostral levels. Stratum pyramidal and radiatum are devoid
of OFQ receptor binding at all levels in this region.
Thalamus
In situ hybridization. At the caudal extent of the
posterior bed nucleus of the stria terminalis, the anterior
part of the paraventricular thalamic nucleus emerges with
high mRNA expression. Low to moderate expression is
observed in the adjacent paratenial nucleus (Fig. 3C). The
rostral anteroventral nucleus, and the anterodorsal and
dorsomedial parts of the anteroventral nucleus have no
mRNA expression (Fig. 7A). Lateral to this midline tha-
lamic group, the reticular nucleus and ventrolateral part
of the anteroventral nucleus contain low to moderate
mRNA expression. The rhomboid nucleus contains low
mRNA expression, with the interanterodorsal, reunions,
anteromedial, and paracentral thalamic nuclei devoid of
mRNA expression rostrally. Further caudal, paratenial
expression decreases slightly and sparse ORL1 mRNA
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expression is observed in the interanterodorsal and an-
terodorsal nuclei. Messenger RNA expression in the para-
ventricular nucleus decreases slightly in the posterior
division, remaining moderate to high to its caudal pole.
At the emergence of the medial habenula, moderate to
high mRNA expression is observed (Fig. 3D). At this level,
the rostral zona incerta also emerges with scattered cells
containing sparse mRNA expression (Fig. 7D). Messenger
RNA expression in zona incerta increases to moderate
levels caudally. The mediodorsal, ventromedial, and ventro-
lateral nuclei at this level are devoid of labeling, and only
sparse mRNA labeling is observed in the caudal anteroven-
tral nucleus, in its ventrolateral and dorsomedial parts,
and the anterodorsal, centromedial, and paracentral nu-
clei. Ventral to the centromedial nucleus, the interantero-
medial nucleus has no detectable mRNA and the reunions
nucleus contains low to moderate mRNA levels.
Further caudal the lateral habenula emerges with,
scattered, sparse mRNA-containing neurons, whereas ex-
pression in the medial habenula and paraventricular
nucleus remain high.At this level, moderate mRNAexpres-
sion is observed in the reunions and rhomboid nuclei, with
low expression in the interanteromedial, ventral postero-
medial, and ventral posterolateral nuclei (Fig. 7C). Sparse
expression is noted in the ventromedial, ventrolateral,
reticular, and laterodorsal nuclei. The mediodorsal tha-
lamic group, and the paracentral, centromedial, gelatino-
sus, and posterior thalamic nuclei are devoid of mRNA
expression at this level. Further caudal, at the emergence
of the posterior paraventricular nucleus, mRNA expres-
sion decreases slightly from that of the anterior division
but remains moderate to high. The lateroposterior, lat-
erodorsal, ventral posterolateral, ventral posteromedial,
ventromedial, and intermediodorsal nuclei all contain
sparse mRNA expression at this level. The subincertal
nucleus at this level has moderate to high expression.
In the mesencephalic thalamus, dense mRNA expres-
sion persists in the posterior paraventricular nucleus, with
moderate to high expression emerging in the precommis-
sural and perifornical nuclei (Fig. 3E). The rostral intersti-
tial nucleus of the medial longitudinal fasciculus and
prerubral field contain moderate mRNAexpression, extend-
ing laterally to scattered, sparse labeling in the fields of
Forel, medial geniculate nucleus, and dorsal geniculate
region (Figs. 3F, 4A). The lateral geniculate nucleus has
moderate mRNA expression. The lateroposterior thalamic
nucleus contains sparse mRNA expression, but this in-
creases caudal into the level of the pretectum, where
mRNA expression is more moderate. At the caudal bound-
aries of the thalamus, the parvicellular part of the subpara-
fascicular thalamic nucleus contains scattered, moder-
ately labeled neurons, adjacent to large moderately
expressing cells in the caudal zona incerta. The posterior,
ethmoid, posterior limitans, and suprageniculate thalamic
nuclei at this level contain sparse mRNA expression.
Orphanin FQ binding The rostral thalamus emerges
with dense binding filling the anterior part of the paraven-
tricular nucleus and the anteroventral nucleus, persisting
throughout these nuclei (Fig. 7A,C). Binding in the parate-
nial nucleus rostrally is moderate to dense, decreasing
slightly at the emergence of the stria medullaris. The
rostral anterodorsal nucleus is conspicuously devoid of
binding. Laterally, the dorsomedial part of the anteroven-
tral thalamic nucleus contains low to moderate OFQ
binding. Binding in the ventrolateral part is moderate to
dense, particularly adjacent to the lateral ventricle. The
reticular nucleus contains moderate binding in a patchy
distribution. Binding is sparse in the anteromedial and
rhomboid nuclei.
In the mid-thalamus, the paracentral nucleus contains
moderate to dense binding in a circumferential distribu-
tion around the paratenial nucleus. At this level, the
interanterodorsal and reunions nuclei contain low levels of
binding. The medial habenula emerges with moderate
binding filling the nucleus. At this level, the mediodorsal
nuclear group is devoid of binding, and the anterodorsal
nucleus contains moderate to dense labeling. The centrome-
dial nucleus contains low levels of binding. The rostral
zona incerta contains low to moderate binding. In the
dorsal thalamus, the ventrolateral part of the laterodorsal
nucleus contains moderate binding, as do the ventrolateral
and ventromedial nuclei (Fig. 7A). Binding is low and
diffuse in the interanteromedial nucleus, negligible in the
anteromedial nucleus, and sparse in the rhomboid nucleus.
The gelatinosus nucleus is conspicuously devoid of orpha-
nin binding at all levels.
At the emergence of the lateral habenula, binding in the
medial habenula intensifies, and dense labeling persists in
the paraventricular nucleus (Fig. 7C). The laterodorsal
nuclei maintain moderate to dense binding. Moderate
levels of receptor binding are seen in the reunions, with
moderate to dense labeling in the adjacent zona incerta.
Low levels of receptor binding seen in the reticular nucleus
spread diffusely through the ventromedial, ventrolateral,
ventral posterolateral, ventral posteromedial (Fig. 7C),
and subincertal nuclei. Moderate binding is observed in
the centrolateral nucleus. The mediodorsal thalamic nu-
clei remain devoid of binding throughout their extent.
In the caudal thalamus, the posterior part of the paraven-
tricular nucleus emerges with lower levels of binding than
in the anterior part, with overall levels remaining moder-
ate to dense. The lateroposterior thalamic nuclei contain
low to moderate binding, as do the posterior and periforni-
cal nuclei throughout their extent. The ventral posterome-
dial nucleus is devoid of binding. The zona incerta at this
level maintains low to moderate binding in its ventral and
dorsal parts, with patchy, sparse binding observed in the
fields of Forel. The adjacent prerubral field and rostral
interstitial nucleus of the medial longitudinal fasciculus
contain diffuse low to moderate OFQ binding. The parvicel-
lular part of the subparafascicular thalamic nucleus is
devoid of binding. The acoustic radiation is conspicuously
devoid of orphanin binding, distinguishing the moderate to
dense binding observed in the lateral geniculate nucleus
from the sparse, diffuse label observed in the medial
geniculate body (Fig. 8A). The adjacent suprageniculate
nucleus also contains sparse binding. The precommissural
and posterior limitans nuclei contain no OFQ binding.
Mesencephalon
In situ hybridization. In the mesencephalon ORL1
mRNA expression is diffuse. However, no mRNA expres-
sion is noted in any of the major fiber bundles, including
the brachium of the inferior or superior colliculus, the
commissure of the inferior or superior colliculus, the
cerebral peduncle, central tegmental tract, dorsal longitu-
dinal fasciculus, fasciculus retroflexus, longitudinal fascicu-
lus, lateral or medial lemniscus, mammillary peduncle,
posterior commissure, rubrospinal tract, superior cerebel-
lar peduncle, or spinal trigeminal tract.
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In the rostral dorsal midbrain, sparse mRNA expression
is observed in the nucleus of the optic tract, the posterior
pretectal nucleus, and olivary pretectal nucleus. Low to
moderate mRNA expression is observed in the dorsal and
ventral parts of the anterior pretectal nucleus, the medial
pretectal nucleus and the nucleus of the posterior commis-
sure. The magnocellular nucleus of the posterior commis-
sure contains moderate to high mRNA expression. Caudal
to the pretectal nuclei, orphanin receptor mRNA expres-
sion in the tectum is generally low. The superior colliculus
emerges with low to moderate mRNA expression at all
levels (Figs. 4A, 8B). The zonal and superficial granular
layers are devoid of mRNA expression, and sparse expres-
sion is observed in the deep gray and deep white layers. In
the intermediate gray, intermediate white and optic nerve
layers, mRNA expression increases slightly and is low to
moderate. At the level of the inferior colliculus, low to
moderate expression is observed in the recess of the
inferior colliculus, increasing slightly into the dorsal cor-
tex where mRNA expression is moderate (Figs. 4C, 8D).
The external cortex and central nucleus of the inferior
colliculus contain only sparse mRNA expression. The
intercollicular nucleus contains sparse to low expression.
Ventral to the tectum, a moderate number of large mRNA-
containing neurons are scattered throughout the deep
mesencephalic nucleus, seen at its emergence in the
rostral midbrain and persisting in this reticular structure
at all levels. In the caudal mesencephalon, the oral part of
the pontine reticular nucleus contains scattered, sparse
mRNA expression throughout.
Laterally, low mRNA expression in the lateral genicu-
late nucleus and sparse expression in the medial genicu-
late nucleus persist to their caudal poles (Figs. 4A, 8B). At
this level, the peripeduncular nucleus contains only sparse
to low mRNA expression, with signal intensifying to
become moderate in the substantia nigra, pars reticulata,
and high in pars compacta (Figs. 4A,B, 8B,D). Messenger
RNA expression in pars lateralis is low at all levels. Caudal
to the substantia nigra, sparse to low mRNA expression is
observed in the nucleus of the brachium of the inferior
colliculus, and the paralemniscal nucleus contains moder-
ate to high expression. The brachium and commissure of
the inferior colliculus contain no mRNA expression. Cau-
dally, sparse expression is observed in the ventral and
intermediate nuclei of the lateral lemniscus. The dorsal
nucleus of the lateral lemniscus contains low mRNA
expression, and the lateral lemniscus is devoid of mRNA
expression.
Several mesencephalic tegmental nuclei contain ORL1
mRNA-expressing cells. Adjacent to the retrorubral field,
the pedunculopontine tegmental nucleus contains low
mRNA expression. Caudally, mRNA expression is sparse
in the microcellular tegmental nucleus and moderate in
the reticulotegmental nucleus. The anterior tegmental
nucleus contains low to moderate mRNA expression in
small-size neurons, and the adjacent subpeduncular teg-
mental nucleus contains a moderate number of slightly
larger-sized mRNA-containing neurons. The rhabdoid
nucleus contains moderate to high mRNA expression.
Numerous large cells in the ventrolateral tegmental
nucleus contain moderate mRNA expression, whereas the
ventral tegmental nucleus only contains sparse expres-
sion. Moderate to high expression is observed in the
laterodorsal tegmental nucleus, adjacent to the dorsal
raphe. The dorsal tegmental nucleus is devoid of mRNA
expression.
At the midline, the central gray contains moderate
mRNA expression ventrally and its dorsal part is filled
with ORL1-containing neurons. High mRNA expression
persists through the entire extent of the central gray (Figs.
3F, 4, 8B,D). Dorsolateral to the central gray, the cunei-
form nucleus is devoid of mRNA expression. Ventral to the
central gray, the nucleus of Darkschewitsch contains low
mRNA expression, with mRNA-containing neurons also
lightly scattered throughout the interstitial nucleus of the
medial longitudinal fasciculus. The medial accessory oculo-
motor nucleus contains moderate to high mRNA expres-
sion. From its emergence rostrally, the Edinger-Westphal
nucleus is filled with densely labeled mRNA-containing
neurons (Fig. 4A). In the caudal mesencephalon, mRNA
expression remains high in the central gray and the
supraoculomotor central gray. The oculomotor nucleus
contains moderate mRNA expression (Fig. 4B). The
paratrochlear nucleus is devoid of mRNA expression,
whereas the trochlear nucleus is filled with densely la-
beled mRNA-expressing cells. The dorsal raphe emerges in
the caudal midbrain with high mRNA expression, filling
the nucleus (Figs. 4C, 8D). This signal intensity extends
ventrally into the caudal linear nucleus of the raphe,
where mRNA expression is slightly decreased but still high
(Fig. 4C). The paramedian raphe contains only sparse,
scattered mRNA-containing neurons, and the median ra-
phe contains moderate to high mRNA expression.
In the ventral midbrain, the rostral interpeduncular
nucleus contains scattered cells expressing low levels of
mRNA. The rostral division contains only sparse mRNA
expression, and the dorsal division is devoid of labeling. In
the caudal interpeduncular nucleus, mRNA expression in
the caudal division is moderate to high (Figs. 4C, 8B) and
rostral division expression remains sparse. The retroru-
bral field and retrorubral nucleus contain low to moderate
mRNA expression rostrally. At the emergence of the red
nucleus, the magnocellular division contains the highest
mRNA expression in the mesencephalon, with numerous,
large, densely labeled neurons filling this structure (Fig.
4B). This level of signal intensity remains throughout the
extent of this nucleus. The parvicellular division of the red
nucleus contains sparse mRNAexpression rostrally, becom-
ing denser at mid-caudal levels, but still much less than
that seen in the magnocellular division. In the adjacent
ventral tegmental region, moderate to high expression is
observed in the ventral tegmental area proper, with high
expression observed in the paranigral nucleus (Figs. 4A,
8B). At the midline, mRNA expression is low in the
interfascicular nucleus, moderate to high in the rostral
linear nucleus of the raphe and parabrachial pigmented
nucleus, and high in the medial terminal nucleus of the
accessory olfactory tract. This pattern persists to the
caudal extent of the ventral midbrain, with the emergence
of the pontine nuclei, which demonstrate high levels of
diffuse mRNA expression (Figs. 5A, 9B).
Orphanin FQ binding. Orphanin binding in the
mesencephalon, like ORL1 mRNA expression, is diffuse.
No binding is noted in the brachium of the inferior or
superior colliculus, the commissure of the inferior or
superior colliculus, the cerebral peduncle, central tegmen-
tal tract, dorsal longitudinal fasciculus, fasciculus retro-
flexus, longitudinal fasciculus, lateral or medial lemnis-
cus, mammillary peduncle, posterior commissure,
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rubrospinal tract, superior cerebellar peduncle, or spinal
trigeminal tract.
In the rostral dorsal midbrain, the nucleus of the
posterior commissure contains low levels of binding, and
the magnocellular nucleus of the posterior commissure is
devoid of OFQ binding. At this level, the perifornical
nucleus contains moderate to dense binding, which per-
sists throughout its extent. The olivary pretectal nucleus
contains dense binding. A low level of binding is observed
in the posterior and medial pretectal nuclei, and sparse
signal is observed in the dorsal and ventral anterior
pretectal nucleus. The nucleus of the optic tract is devoid of
orphanin binding. Caudal to the pretectal nuclei, the
superior colliculus emerges with dense labeling in its zonal
and superficial gray layers (Fig. 8A). Dense binding re-
mains within these layers to its caudal extent. Binding in
the intermediate gray layer is sparse, and in the deep gray
layer low to moderate. The optic nerve, intermediate white
and deep white layers are devoid of binding. Caudally, the
nucleus of the brachium of the inferior colliculus contains
sparse binding. The inferior colliculus emerges with low
levels of binding in the central and intercollicular nuclei,
and low binding in its dorsal and external cortices (Fig.
8C). The recess of the inferior colliculus is devoid of OFQ
binding. The deep mesencephalic nucleus contains only
sparse binding, and the oral part of the pontine reticular
formation contains patches of low to moderate labeling.
In the lateral midbrain, moderate binding is seen in the
lateral geniculate nucleus, and sparse binding in the
medial geniculate nucleus that persists to their caudal
extent (Fig. 8A). The peripeduncular nucleus at this level
contains moderate to high levels of OFQ binding, with
density of binding sites decreasing slightly into the substan-
tia nigra, pars compacta, and pars reticulata, where a
moderate density of binding sites is observed at all levels
(Fig. 8A,C). Binding in pars lateralis is low. The dorsal
nucleus of the lateral lemniscus contains sparse to low
binding. In the paralemniscal nucleus, and the lateral and
ventral nuclei of the lateral lemniscus, no detectable
orphanin binding is observed.
The tegmental nuclei of the basal mesencephalon con-
tain little OFQ binding. Adjacent to the retrorubral field,
the pedunculopontine tegmental nucleus contains only
sparse binding. Caudal and laterally, the microcellular
tegmental nucleus has no detectable orphanin binding,
with negligible to sparse binding in the reticulotegmental
nucleus. The anterior tegmental nucleus contains low to
moderate binding, and the adjacent rhabdoid nucleus
shows no binding. Just ventral to the decussation of the
superior cerebellar peduncle, the subpeduncular tegmen-
tal nucleus is devoid of OFQ binding. In the caudal
mesencephalon, the ventrolateral, dorsal, and ventral
tegmental nuclei contain no detectable orphanin binding.
The laterodorsal tegmental nucleus stands out at this level
with moderate to dense binding at the level of the caudal
dorsal raphe.
At the midline, the central gray emerges with moderate
to dense binding rostrally, becoming more dense caudally,
in its dorsal division. This dense central gray binding
persists to its caudal extent (Fig. 8A). Dorsal to the central
gray, the cuneiform nucleus has no binding. Ventrally, the
nucleus of Darkschewitsch contains sparse, patchy bind-
ing, and the interstitial nucleus of the medial longitudinal
fasciculus has no detectable orphanin binding. The Edinger-
Westphal nucleus at this level is filled with a dense
number of orphanin binding sites, which persists to its
caudal pole (Fig. 8A). Binding extends ventrally from this
nucleus onto the rostral linear nucleus of the raphe,
decreasing in intensity, but still moderate to dense. The
medial accessory oculomotor nucleus contains low to mod-
erate binding, with signal intensity in the supraoculomo-
tor central gray very dense throughout. In contrast to
ORL1 mRNA expression, no binding is observed in the
paratrochlear, oculomotor, or trochlear nuclei. At the emer-
gence of the dorsal raphe, dense binding is noted filling
this nucleus. Binding remains high in this structure
throughout the mesencephalon (Fig. 8C). Ventral to the
dorsal raphe, receptor binding diminishes slightly into the
caudal linear raphe, where it remains moderate to high.
The paramedian and median raphe also contain moderate
to high levels of binding throughout their rostral to caudal
extent.
In the ventral mesencephalon, the interpeduncular
nucleus contains dense OFQ binding in the caudal and
lateral divisions (Fig. 8A). The dorsal and rostral divisions
of this nucleus, however, are devoid of orphanin binding.
The retrorubral field and retrorubral nucleus have no
detectable orphanin binding. In contrast to the high levels
of ORL1 mRNA expression observed in the red nucleus,
orphanin binding in this structure is sparse to negligible in
both the parvicellular and magnocellular divisions. The
adjacent ventral tegmental region contains generally low
orphanin binding. Receptor binding levels are low in the
ventral tegmental area proper, sparse in the adjacent
paranigral nucleus, and sparse in the parabrachial pig-
mented nucleus (Fig. 8A). At the midline, the interfascicu-
lar nucleus contains moderate binding, becoming moder-
ate to dense in the rostral linear raphe and medial
terminal nucleus of the accessory olfactory tract. At the
caudal extent of the ventral mesencephalon, the pontine
nuclei emerge filled with dense binding that extends into
the metencephalon (Fig. 9A).
Cerebellum
In situ hybridization. Cerebellar ORL1 mRNAexpres-
sion is confined to the deep cerebellar nuclei. Messenger
RNA expression detected within the granular, molecular,
or Purkinje cell layer of the cerebellar lobules at all levels
was nonspecific and did not differ with sense or antisense
probes. Within the deep cerebellar nuclei, the lateral
(dentate) nucleus is filled with numerous, large mRNA-
expressing cells. Unlike that observed in the cerebellar
lobules, mRNA expression in these cells is specific and
persists to its caudal boundaries. In the parvicellular part
of the dentate nucleus, mRNAexpression decreases slightly
and remains moderate to its caudal extent. The anterior
part of the interposed cerebellar nucleus contains minimal
expression rostrally, with expression becoming moderate
to high from mid to caudal levels. The posterior part of the
interposed nucleus contains low to moderate mRNAexpres-
sion at all levels, with similar expression in the dorsolat-
eral and dorsomedial divisions. The medial (fastigial)
cerebellar nucleus contains moderate to high mRNAexpres-
sion at all levels, extending into its dorsolateral protuber-
ance.
Orphanin FQ binding. No specific orphanin binding
is observed in the cerebellar lobules, with the granular,
molecular, and Purkinje cell layers devoid of specific
labeling. Specific orphanin binding in the deep cerebellar
nuclei is present but minimal. The interposed nucleus of
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the cerebellum is devoid of OFQ binding, in its anterior,
dorsomedial, dorsolateral, and posterior parts. The lateral
(dentate) nucleus contains low to moderate binding at all
levels, but no binding is observed in its parvicellular part.
Sparse, patchy binding is observed in the medial (fastigial)
nucleus, mostly in its lateral boundary. The dorsolateral
protuberance of the fastigial nucleus, has no detectable
orphanin binding.
Metencephalon
In situ hybridization. Orphanin receptor mRNA ex-
pression is high throughout the pons. No expression was
observed in major fiber bundles, including the superior
cerebellar peduncle, inferior cerebellar peduncle, pyrami-
dal tract, abducens nerve, facial nerve, vestibulocochlear
nerve, sensory root of the trigeminal nerve, medial longitu-
dinal fasciculus, and trapezoid body. Rostrally in the pons,
the motor trigeminal nucleus emerges with high mRNA
expression (Fig. 9B). The nucleus is filled with numerous
large, densely labeled neurons. Lateral to the motor tri-
geminal nucleus, the principal sensory trigeminal nucleus
also contains numerous, large ORL1-expressing neurons,
diffusely filling the dorsomedial division. The ventrolat-
eral division of the principal sensory trigeminal nucleus
has no detectable mRNA expression. Adjacent to the
principal trigeminal nucleus, the A7 cell region contains
low to moderate mRNA expression and the Kolliker-Fuse
nucleus contains sparse mRNA expression. The tegmental
nuclei in the metencephalon show very little mRNAexpres-
sion. The posterodorsal tegmental nucleus contains sparse,
scattered mRNA expression, and the dorsal and dorsome-
dial tegmental nuclei have no detectable mRNA expres-
sion.
In the rostral dorsal pons, mRNA expression in the
dorsal raphe is significantly less than that observed in the
mesencephalon. The metencephalic portion of this nucleus
contains moderate to high mRNA expression to its caudal
extent (Figs. 5A, 9B). The pontine central gray at this level
contains low to moderate mRNA expression. Further cau-
dal, the mesencephalic trigeminal nucleus emerges with
high mRNA expression. Numerous, large mRNA-express-
ing neurons are observed filling this nucleus at all levels.
The locus coeruleus is filled with numerous, densely
labeled neurons and is one of the highest mRNA-express-
ing regions in the metencephalon (Figs. 5A, 9B). High
mRNA expression in this structure persists to its caudal
extent at the genu of the facial nerve. Laterally, the medial
parabrachial nucleus contains only scattered neurons with
sparse mRNA expression, whereas the lateral parabra-
chial nucleus contains high levels of mRNA expression
(Figs. 5A, 9B). The a division of the subcoeruleus nucleus
contains low to moderate mRNA expression, and Barring-
ton’s nucleus has no detectable mRNA expression. Later-
ally, the anterior ventral cochlear nucleus contains sparse
mRNA expression.
In the caudal dorsal pons, the abducens nucleus emerges
filled with numerous, large mRNA-expressing neurons.
The adjacent para-abducens nucleus contains less mRNA
expression but still is moderately to densely labeled.
Laterally, the posterior ventral cochlear nucleus contains
moderate to high mRNA expression, with expression in the
adjacent dorsal cochlear nucleus low to moderate. At the
level of the genu of the facial nerve, the supragenual
nucleus contains no mRNA expression. Laterally, the
vestibular nuclear complex emerges with low to moderate
mRNA expression in the superior vestibular nucleus. At
this level, the medial vestibular nucleus contains high
mRNA expression diffusely distributed throughout the
nucleus, extending into its ventral division (Fig. 5B). The
lateral vestibular nucleus contains moderate mRNAexpres-
sion. Moderate mRNA expression is also observed in the
spinal vestibular nucleus in the caudal pons. Ventral to the
vestibular complex, numerous large, densely labeled neu-
rons are observed in the dorsomedial spinal trigeminal
nucleus. Pars oralis of the spinal trigeminal nucleus is also
filled with high expressing cells at this level (Fig. 5B).
In the ventral pons just caudal to the pontine nuclei, the
nucleus of the trapezoid body emerges with moderate
mRNA expression persisting throughout its extent. Just
lateral to the nucleus of the trapezoid body, the rostral
periolivary region contains low to moderate mRNA expres-
sion. Further caudal, the medioventral and lateroventral
periolivary nuclei of the superior olive contain moderate
mRNA expression. The adjacent superior paraolivary
nucleus and dorsal periolivary nucleus contain moderate
to high mRNA expression. The lateral superior olive
contains the highest mRNA expression of the superior
olivary complex, with numerous ORL1-containing neurons
filling the nucleus at all levels. The caudal periolivary
nucleus contains low to moderate mRNA expression and
the medial superior olive has no detectable mRNA expres-
sion. Lateral to the olivary complex the A5 cell region
contains moderate mRNA expression (Figs. 5B, 9D). In the
caudal pons, mRNA expression is high, filling the region of
the A5 cell group. Caudal to the superior olive, the nucleus
of the facial nerve emerges with high mRNA expression.
Large, densely labeled neurons fill this nucleus at all
levels, making it the most densely labeled structure in the
metencephalon. Densely labeled ORL1-containing cells fill
this nucleus to its caudal extent into the medulla (Figs. 5B,
9D).
At the midline, the raphe magnus emerges with high
mRNA expression. Large, densely labeled neurons fill this
structure and persist to its caudal extent. Caudally, mRNA
expression extends from raphe magnus into the raphe
pallidus nucleus, where high mRNA expression is also
observed (Figs. 5B, 9D,F). The pontine raphe nucleus
contains moderate to high mRNA expression at all levels.
Message expression within this ventral raphe complex
persists into the medulla. Within the reticular formation,
the pontine reticular nucleus contains low to moderate
mRNA expression rostrally, with large mRNA-containing
cells scattered throughout the ventral and caudal parts
(Fig. 5A). Further caudal, at the level of the facial nucleus,
mRNA expression increases dramatically in this region.
The caudal pontine reticular nucleus is filled with densely
labeled, large neurons. Messenger RNA expression in the
ventral nucleus is moderate to high. Laterally, the interme-
diate reticular nucleus contains low mRNA expression and
the parvicellular reticular nucleus contains only sparse
mRNA expression at all levels. In the caudal ventral pons,
the gigantocellular reticular nucleus emerges with low to
moderate mRNA expression, slightly increased in its alpha
division (Figs. 5B, 9D). The lateral paragigantocellular
reticular nucleus has sparse mRNA expression.
Orphanin FQ binding. Although less widespread
than ORL1 mRNA expression, orphanin binding is still
quite extensive in the metencephalon. No OFQ binding
was observed in major fiber bundles, including the supe-
rior cerebellar peduncle, inferior cerebellar peduncle, pyra-
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midal tract, abducens nerve, facial nerve, vestibuloco-
chlear nerve, medial longitudinal fasciculus, sensory root
of the trigeminal nerve and trapezoid body. Rostrally, the
motor trigeminal nucleus contains low to moderate bind-
ing (Fig. 9A), with binding in the adjacent principal
sensory trigeminal nucleus high in its dorsomedial divi-
sion and only low to moderate in the ventrolateral part.
Just dorsal to the rostral principal sensory nucleus, the A7
cell region and Kolliker-Fuse nucleus contain low to moder-
ate binding. The dorsal, dorsomedial, and posterodorsal
tegmental nuclei in the pons have no detectable orphanin
binding.
In the rostral dorsal pons, the dorsal raphe demon-
strates high levels of orphanin binding. This binding
pattern persists to the caudal extent of this structure
(Figs. 8C, 9A). The adjacent pontine central gray contains
moderate to high OFQ binding at all levels. The mesence-
phalic trigeminal nucleus, in contrast to ORL1 mRNA
expression, has no detectable orphanin binding at all
levels. Adjacent to this nucleus, the locus coeruleus is
diffusely filled with dense OFQ binding. This binding
pattern persists in the locus coeruleus to its caudal extent
(Fig. 9A). Laterally, the medial parabrachial nucleus con-
tains sparse binding, whereas binding in the lateral para-
brachial nucleus is moderate to dense (Fig. 9A). Binding in
the a division of the subcoeruleus nucleus is low and in
Barrington’s nucleus is sparse. Laterally, the granular
layer of the anterior ventral cochlear nucleus is filled with
moderate to dense OFQ binding.
In the caudal dorsal pons, the abducens nucleus con-
tains low levels of binding, in marked contrast to the high
ORL1 mRNA expression observed in this nucleus. The
adjacent para-abducens nucleus has no detectable OFQ
binding. Laterally, the posterior ventral cochlear nucleus
and dorsal cochlear nucleus are densely labeled with OFQ
binding. At the genu of the facial nerve, in contrast to the
paucity of orphanin receptor mRNA expression in this
structure, the supragenual nucleus shows high levels of
orphanin binding. Binding in the vestibular nuclear com-
plex is generally moderate. The superior vestibular nucleus
emerges rostrally with low to moderate binding. The
adjacent medial vestibular nucleus contains moderate to
dense binding, with low levels of binding observed in its
ventral subdivision (Fig. 9C). The lateral vestibular nucleus
shows no detectable orphanin binding, and binding in the
spinal vestibular nucleus is sparse to negligible. Ventral to
the vestibular complex in the caudal metencephalon, the
dorsomedial spinal trigeminal nucleus and the pars oralis
of the spinal trigeminal nucleus contain moderate orpha-
nin binding (Fig. 9C).
In the ventral pons, the nucleus of the trapezoid body
emerges with moderate OFQ binding, the intensity persist-
ing to the caudal extent of this nucleus. Lateral to the
nucleus of the trapezoid body, the superior olivary nuclear
complex generally contains minimal binding. Rostrally,
moderate binding is observed in the rostral periolivary
area. Caudal to this structure, the medioventral and
lateroventral periolivary nuclei show no OFQ binding.
Binding in the superior paraolivary nucleus and dorsal
periolivary nucleus is sparse. The lateral superior olive
and medial superior olive have no detectable orphanin
binding. The caudal periolivary nucleus contains low to
moderate binding. Lateral to the olivary complex, the
region of the A5 cell group contains low to moderate
orphanin binding. Caudal to the superior olive, binding in
the facial nucleus is moderate (Fig. 9C). Although much
decreased in intensity to that observed for ORL1 mRNA
expression, binding in this nucleus remains dense to its
caudal extent into the rostral medulla.
At the pontine midline, the raphe magnus emerges with
negligible binding. The raphe pallidus nucleus and pontine
raphe nucleus show no detectable OFQ binding at this
level. Further caudally, the pontine raphe nucleus remains
devoid of binding, but orphanin binding intensity in-
creases dramatically in the other ventral raphe nuclei. At
the level of the facial nucleus, binding in the raphe
pallidus nucleus is moderate and in the raphe magnus is
low to moderate (Fig. 9C,E). This binding pattern becomes
slightly more dense into the medulla. Within the reticular
formation, the pontine reticular nucleus contains only
sparse binding in its caudal division (Fig. 9A) and low to
moderate in the ventral division. Further caudal, the
intermediate reticular nucleus contains only sparse bind-
ing and the parvicellular reticular nucleus shows low to
moderate binding. In the caudal pons, binding in the
gigantocellular reticular nucleus is low to moderate. The
lateral paragigantocellular reticular nucleus and the al-
pha division of the gigantocellular reticular nucleus show
no detectable OFQ binding.
Myelencephalon
In situ hybridization. As seen in the metencephalon,
orphanin receptor mRNA expression is high and wide-
spread in the medulla. No mRNA expression is observed in
major fiber bundles in this region, including the inferior
cerebellar peduncle, vagal nerve, hypoglossal nerve, me-
dial longitudinal fasciculus, pyramidal tract, solitary tract,
and spinal trigeminal tract. In the rostral dorsal medulla,
the region of the C3 cell group contains no mRNA-
expressing cells. Further caudal, in the region of the C2
cell group, moderate to high mRNA expression is noted,
medial to the nucleus of the solitary tract. The prepositus
hypoglossus contains sparse mRNA expression rostrally
and, at caudal levels, numerous large mRNA-expressing
neurons fill this structure (Fig. 9D). The caudal interstitial
nucleus of the medial longitudinal fasciculus has no detect-
able mRNA expression. Caudal to the prepositus hypoglos-
sus, the dorsal motor nucleus of the vagal nerve contains
high mRNA expression. The hypoglossal nucleus is packed
with cells expressing high levels of mRNA, filling the
nucleus to its caudal extent (Figs. 9F, 10B). The interca-
lated nucleus of the medulla has no mRNA expression.
In the medullary vestibular nuclear complex, mRNA
expression remains unchanged, with moderate expression
in the medial vestibular nucleus, low expression in the
ventral part of the medial nucleus, sparse expression in
the spinal vestibular nucleus and moderate expression in
the lateral vestibular nucleus (Fig. 9D). This pattern
persists to the caudal extent of the vestibular complex.
Lateral to the spinal vestibular nucleus, the external
cuneate nucleus contains sparse, scattered ORL1-contain-
ing neurons. The nucleus of the solitary tract emerges in
the rostral medulla with moderate mRNA expression. This
pattern of expression persists caudally, where mRNA
expression in the lateral and medial divisions is moderate,
and the central division demonstrates high levels of mRNA
expression (Figs. 9F, 10B). The high levels of mRNA
expression in the central part of the solitary nucleus is in
contrast to the paucity of mRNA expression observed in
the area postrema and, further caudal, the median acces-
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sory nucleus of the medulla (Fig. 9F). At the lateral border
of the central solitary nucleus, the region of the A2 cell
group contains moderate mRNA expression. The solitary
tract has no detectable mRNA expression. In the caudal
dorsal medulla, the cuneate nucleus contains moderate
mRNA expression, and the gracile nucleus has only sparse
expression (Fig. 10B). Laterally, the paratrigeminal nucleus
contains moderate mRNA expression.
Laterally, the spinal trigeminal nucleus in the rostral
medulla contains high mRNA expression in its oral part
and moderate in the dorsomedial part (Figs. 5B, 9C). The
interpolar division of this nucleus emerges with high
mRNA expression, persisting into the caudal myelencepha-
lon where the pars caudalis of the spinal trigeminal
nucleus contains moderate to high mRNA expression
(Figs. 9E, 10B). In the medullary reticular formation,
mRNA expression is sparse to negligible in the parvicellu-
lar reticular nucleus and intermediate reticular nucleus.
Medially in the rostral medulla, the gigantocellular reticu-
lar nucleus contains low to moderate mRNA expression,
with moderate to high expression in its ventral division.
The lateral paragigantocellular reticular nucleus contains
negligible mRNA expression, and the adjacent rostroven-
triculolateral reticular nucleus contains very high mRNA
expression. Caudal to the paragigantocellular reticular
nucleus, the lateral reticular nucleus emerges with high
mRNA expression, filling this region with large-sized cells
(Fig. 10B). High mRNA expression persists in the rostro-
ventriculolateral reticular nucleus at this level, in its
lateral and medial components. Posterior to the gigantocel-
lular reticular nucleus, mRNA expression falls off in the
caudal medullary reticular region, with moderate mRNA
expression observed in the dorsal and ventral medullary
reticular nuclei, and negligible expression in the interme-
diate reticular nucleus. This pattern persists to the caudal
extent of the myelencephalon.
In the rostral ventral medulla, just caudal to the facial
motor nucleus, high mRNA expression is observed the
region of the C1 cell group and the rostroventriculolateral
reticular nucleus. This persists caudally into the region of
the A1 cell group, where mRNA expression remains high to
its caudal extent. At this level, the nucleus ambiguous
emerges with high mRNA expression, providing some of
the highest mRNA expression in the medulla (Fig. 9F).
Further caudal, intensity of mRNA expression decreases
slightly into the retroambiguous nucleus. At the emer-
gence of the inferior olivary complex, the principal and
dorsal nuclei contain moderate to high mRNA expression,
with low to moderate expression in the medial nucleus and
dorsomedial cell group (Fig. 10B). Caudal to the principal
olivary nucleus, mRNA expression falls off in the inferior
olivary complex, with sparse mRNA expression in sub-
nucleus A and subnucleus B, low to moderate expression in
the medial nucleus, and persistent moderate expression in
the dorsal nucleus. At the ventral midline, the raphe
magnus is filled with dense mRNA expression in the
rostral medulla and persists throughout the myelencepha-
lon (Fig. 9F). Adjacent to raphe magnus, the raphe pallidus
nucleus contains high mRNA expression, and the raphe
obscurus nucleus contains moderate mRNA expression,
which persists to its caudal extent, at the pyramidal
decussation (Fig. 10B).
Orphanin FQ binding. Similar to ORL1 mRNA ex-
pression, OFQ binding in the myelencephalon is wide-
spread and not observed within major medullary fiber
bundles. One exception is the caudal spinal trigeminal
tract, which contains some OFQ binding (discussed below).
In the rostral dorsal medulla, the region of the C3 cell
groups is devoid of orphanin binding and binding in the C2
cell region is low to moderate. Just caudal to the supra-
genual nucleus of the pons, dense orphanin binding is
observed in the prepositus hypoglossus, persisting to its
caudal pole (Fig. 9C). Caudal to the prepositus hypoglos-
sus, the dorsal motor vagal nucleus contains moderate
binding. Binding in the hypoglossal nucleus is sparse (Fig.
9E). Adjacent to the hypoglossal nucleus, the intercalated
nucleus of the medulla and the caudal interstitial nucleus
of the medial longitudinal fasciculus have no detectable
orphanin binding.
In the medullary vestibular nuclear complex, the medial
vestibular nucleus and ventral medial vestibular nucleus
have moderate OFQ binding. Binding is sparse in the
spinal vestibular nucleus and negligible in the lateral
vestibular nucleus (Fig. 9C). Laterally, the external cune-
ate nucleus contains moderate to dense binding. At this
level, the nucleus of the solitary tract emerges with sparse
binding initially, increasing to become low to moderate in
the lateral and medial divisions more caudally. This pat-
tern persists into the caudal part of this structure, where
binding intensifies and becomes dense in the central
division (Figs. 9E, 10A). The adjacent area postrema at
this level contains moderate to high levels of binding (Fig.
9E), and binding in the region of the A2 cell group is low to
moderate. At the caudal pole of the nucleus of the solitary
tract, the median accessory nucleus of the amygdala is
filled with cells expressing high levels of orphanin binding.
In the caudal dorsal medulla, binding is modest in the
paratrigeminal and cuneate nuclei, and sparse to negli-
gible in the gracile nucleus (Fig. 10A).
In the rostral lateral medulla, the spinal trigeminal
nucleus, pars oralis contains moderate binding. This bind-
ing intensity persists into the interpolar and dorsomedial
parts of the medullary spinal trigeminal nucleus, increas-
ing dramatically into the caudal medullary region (Fig.
9E). At this level, OFQ binding is dense throughout the
pars caudalis of the spinal trigeminal nucleus, making it
one of the most densely labeled structures in the medulla.
Orphanin binding extends from the spinal trigeminal
nucleus into the caudal spinal trigeminal tract, making
this the only major fiber bundle in the CNS with OFQ
binding (Fig. 10A). This binding pattern persists into the
spinal cord.
Orphanin binding in the medullary reticular formation
is generally low. Binding in the parvicellular reticular
nucleus is low to its caudal extent. The intermediate
reticular nucleus contains only sparse orphanin binding.
Medially, the gigantocellular reticular nucleus contains
low to moderate orphanin binding, more moderate in its
ventral division. At this level, the lateral paragigantocellu-
lar reticular nucleus has no detectable OFQ binding, and
the dorsomedial paragigantocellular reticular nucleus con-
tains only sparse to low levels of binding. Laterally, the
rostroventriculolateral reticular nucleus contains low to
moderate binding, and binding in the lateral reticular
nucleus is low (Fig. 10A). The ventral medullary reticular
nucleus contains low to moderate binding at all levels,
whereas the dorsal medullary reticular nucleus contains
low levels of binding rostrally and dense labeling at the
level of the pyramidal decussation (Fig. 10A).
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In the ventral medulla, low to moderate binding is
observed in the region of the C1 cell group within the
rostroventriculolateral reticular nucleus. This binding pat-
tern persists to the A1 cell group caudally. At this anatomic
level, the nucleus ambiguous emerges with dense OFQ
binding. Orphanin binding decreases to some degree into
the retroambiguous nucleus where it is only moderate.
Dense binding is observed throughout the inferior olive,
persisting throughout the entire ventral medulla (Fig.
10A). Rostrally, moderate binding is observed in the dorsal
nucleus of the inferior olive and dense binding in the
principal nucleus. The dorsomedial cell group contains
moderate binding, and the medial nucleus of the inferior
olive emerges with dense binding. This pattern persists
caudally, with moderate binding noted in subnucleus B of
the olivary complex. Subnucleus A of the inferior olive
emerges with dense OFQ binding, persisting to the caudal
medulla with some of the most dense orphanin binding
seen in this region. At the caudal pole of the inferior olive,
the medial nucleus is filled with dense OFQ binding.
Adjacent to the inferior olivary complex, the raphe magnus
contains moderate binding (Fig. 9E). This level persists to
its caudal extent. The adjacent raphe pallidus nucleus
contains dense binding throughout. This dense binding
persists to the caudal extent of the medulla. The raphe
obscurus contains only low to moderate binding (Fig. 10A).
Spinal cord
In situ hybridization. In the cervical spinal cord,
ORL1 mRNA expression is higher in the ventral horn than
the dorsal horn (Fig. 10D). Messenger RNA-containing
cells in the dorsal horn are confined mostly to the deeper
laminae. No orphanin receptor mRNA expression is ob-
served in lamina I, and only scattered mRNA-containing
cells are noted in lamina II. Messenger RNA expression
becomes slightly stronger in laminae III and IV, where low
to moderate expression is observed. Laminae V and VI
contain moderate to high mRNA expression, extending
medially to lamina X, where scattered neurons with only
low mRNA expression are observed. The highest ORL1
mRNA expression in the cervical spinal cord is in laminae
VIII and IX of the ventral horn. In this region, numerous,
large ventral horn cells containing abundant mRNAexpres-
sion are widely distributed, slightly more concentrated in
lamina IX.
In the thoracic spinal cord, the ORL1 mRNA expression
pattern is very similar to that of the cervical cord. No
mRNA expression is observed in lamina I, and laminae II
and III contain only scattered mRNA-expressing cells.
Layer V in the thoracic region has very sparse mRNA
expression, and lamina IV contains moderate expression.
Laminae VII and VIII contain scattered, large neurons
with moderate mRNA expression, spreading medial to
lamina X, where expression is also moderate. The ventral
horn, similar to that seen in the cervical region, contains
numerous large, densely labeled neurons, with most
mRNA-expressing neurons within lamina IX. High mRNA
expression is observed in the intermediomedial cell col-
umn and in the intermediolateral column.
The dorsal root ganglion is filled with numerous, large
mRNA-expressing neurons. These neurons are located
widely throughout the ganglion and contain high mRNA
expression (Fig. 10D). In other areas of the spinal cord, the
central cervical nucleus contains low to moderate mRNA
expression, and the lateral cervical and lateral spinal
nuclei contain sparse mRNA expression. No mRNA expres-
sion is observed in the cuneate fasciculus, the dorsal
corticospinal tract, lateral funiculus, or ventral funiculus.
Orphanin FQ binding. In contrast to ORL1 mRNA
distribution in the spinal cord, orphanin binding is higher
in the dorsal horn than in the ventral horn (Fig. 10A). In
the cervical spinal cord, lamina I contains no OFQ binding.
Binding then increases significantly, becoming dense in
lamina II and remaining moderate to dense in lamina III.
Binding intensity decreases significantly into the deeper
laminae of the dorsal horn, becoming low in lamina IV and
V. More moderate binding is observed in lamina VI, but the
density of binding sites falls off into the ventral horn, with only
low levels of binding observed in laminae VII, VIII, and IX.
Lamina X contains moderate binding, diffusely localized.
In the thoracic spinal cord, no binding is noted in lamina
I and only low binding is noted in lamina II. The density of
binding sites increases significantly, with moderate bind-
ing in lamina III and high levels of binding noted in lamina
IV. This level of binding extends medially into lamina X,
where very dense orphanin binding is noted. Into the
ventral horn, low levels of binding are noted in laminae VII
and VIII.
In marked contrast to ORL1 mRNA expression, no
orphanin binding is observed in the dorsal root ganglia
(Fig. 10A). In the remaining areas of the spinal cord, low to
moderate binding is observed in the intermediomedial cell
column, with moderate to dense binding in the intermedio-
lateral cell column. Other than sparse labeling noted in
the central cervical nucleus, the remainder of the spinal
cord has no detectable orphanin binding, including the
lateral cervical and lateral spinal nuclei, cuneate fascicu-
lus, dorsal corticospinal tract, lateral funiculus, and ven-
tral funiculus.
DISCUSSION
ORL1 mRNA expression and OFQ binding
Both in situ hybridization and 125I-[14Tyr]-OFQ peptide
binding demonstrate a wide-spread distribution of ORL1
receptor in the adult male rat brain. Our in situ hybridiza-
tion findings are in good agreement with earlier studies of
ORL1 mRNA distribution in the rat and mouse (Bunzow et
al., 1994; Fukuda et al., 1994; Mollereau et al., 1994; Wick
et al., 1994; Lachowicz et al., 1994). In addition, the
125I-[14Tyr]-OFQ peptide, in our hands, demonstrates a
high affinity for the ORL1 receptor, similar to that previ-
ously observed for [14Tyr]-OFQ (Ardati et al., 1997).
In the present study, distribution of ORL1 mRNA expres-
sion correlated closely with that of 125I-[14Tyr]-OFQ bind-
ing in most CNS regions. In general, most areas that
contained mRNA expression also demonstrated some de-
gree of receptor binding. Additionally, almost every region
with dense OFQ binding also contained mRNA-expressing
cells. This close correlation was observed in all cortical
regions, including the neocortex, orbital cortex, insular
cortex, cingulate cortex, entorhinal cortex, piriform cortex
and retrosplenial cortex. It was also observed in the
anterior olfactory nucleus, diagonal band, lateral septum,
claustrum, endopiriform nuclei, globus pallidus, substan-
tia nigra, most divisions of the medial preoptic area and
bed nucleus of the stria terminalis, multiple hypothalamic
nuclei, including the anterior hypothalamus, arcuate
nucleus, mammillary region, paraventricular nucleus, pos-
terior hypothalamus and ventromedial nucleus, the ante-
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rior cortical, basolateral, medial and posterior cortical
amygdaloid nuclei, the stratum oriens of Ammon’s horn,
the subiculum and multiple thalamic nuclei, including the
anteroventral nucleus, habenula, lateral geniculate
nucleus, paratenial nucleus, paraventricular nucleus, re-
unions, rhomboid nucleus, reticular nucleus, and zona
incerta. In the brainstem, close correlation was observed
in the central gray, raphe nuclei, inferior colliculus,
Edinger-Westphal nucleus, interpeduncular nucleus, pre-
commissural nucleus, perifornical nucleus, pontine nuclei,
peripeduncular nucleus, motor nuclei of the abducens and
facial nerves, A5 cell region, superior olivary region, locus
coeruleus, lateral parabrachial nucleus, several vestibular
nuclei, the principal and sensory nuclei of the trigeminal
nerve, the nucleus of the trapezoid body, ventral cochlear
nucleus, motor nucleus of the vagal nerve, A1, A2, and A7
cell regions, nucleus ambiguous, multiple nuclei of the
brainstem reticular system, several divisions of the infe-
rior olive, the rostral ventrolateral medulla, the retroam-
biguous nucleus, and nucleus of the solitary tract. In the
spinal cord, each of laminae II–X contained varying levels
of both mRNA expression and OFQ binding.
Despite the immense number of structures that con-
tained both ORL1 mRNA expression and OFQ binding,
there were some notable exceptions where mismatch oc-
curred between ORL1 mRNA expression and orphanin
receptor binding. High ORL1 mRNA expression was ob-
served in several regions in which no detectable 125I-[14Tyr]-
OFQ binding was observed. This was noted in several
forebrain structures, including the basal nucleus of Mey-
nert, posterolateral and medial posteromedial divisions of
the bed nucleus of the stria terminalis, medial preoptic
nucleus, periventricular and supraoptic nuclei of the hypo-
thalamus, amygdalopiriform transition area, basomedial
amygdala, the pyramidal layer of area CA3, the dentate
gyrus granule cell and polymorph layers, the precommis-
sural, and ventral posteromedial nuclei of the thalamus.
In the midbrain, this pattern was observed in the oculomo-
tor and trochlear motor nuclei, parabigeminal nucleus,
parabrachial pigmented nucleus, magnocellular nucleus of
the posterior commissure, red nucleus, retrorubral field,
and the optic and intermediate layers of the superior
colliculus. In the cerebellum, the interposed, lateral and
medial deep nuclei all contain abundant ORL1 mRNA
expression, with only slight binding in the lateral nucleus.
In the metencephalon, the abducens and facial motor
nuclei contain high mRNA expression. Both cranial nerve
nuclei contain 125I-[14Tyr]-OFQ binding, but markedly
lower density of receptor sites. In addition, high mRNA
expression is observed in the alpha subdivision of the
gigantocellular and caudal pontine reticular nuclei, lateral
superior olive, lateral vestibular nucleus, lateroventral
and medioventral preolivary nuclei, mesencephalic trigemi-
nal nucleus, para-abducens nucleus, and pontine raphe
nucleus. In all of these structures, OFQ binding is negli-
gible. In the myelencephalon, dense mRNA expression is
observed in the hypoglossal nucleus and dorsal motor
nucleus of the vagal nerve, whereas orphanin binding is
negligible in the hypoglossal nucleus and significantly
decreased in the dorsal motor vagal nucleus. No other
medullary region exhibits such dissimilarity. The disparity
of ORL1 expression and OFQ binding is also marked in the
spinal cord. In the cervical spinal cord, ORL1 mRNA
expression is high in laminae VIII and IX of the ventral
horn, where 125I-[14Tyr]-OFQ binding is low. Moderate to
high mRNA expression is also observed in lamina V,
another area where OFQ binding is negligible. In the
thoracic spinal cord, this disparity is most pronounced in
laminae VIII and IX. The dorsal root ganglion is densely
filled with cell bodies containing high mRNA expression,
but is devoid of OFQ binding.
There were very few notable CNS regions where 125I-
[14Tyr]-OFQ binding is dense, whereas ORL1 mRNAexpres-
sion is negligible or absent. These regions of disparity
include the glomerular layer of the olfactory bulb, the
medial mammillary nucleus, suprachiasmatic nucleus,
tuber cinereum, molecular layer of the dentate gyrus and
multiple thalamic nuclei (anteroventral, laterodorsal, para-
central, and ventromedial), the olivary pretectal nucleus,
the zonal and superficial gray layers of the superior
colliculus, supragenual nucleus, anterior ventral cochlear
nucleus, external cuneate nucleus, medial subnucleus A
and B of the inferior olive, dorsal medullary reticular
nucleus, and median accessory nucleus of the medulla. All
of these structures contain abundant OFQ binding with
negligible ORL1 mRNA expression. In the spinal cord,
lamina II in the cervical region and lamina III in the
thoracic region also demonstrate this disparity. The spinal
trigeminal tract, the only fiber bundle in the CNS that
demonstrates OFQ binding, is also devoid of ORL1 mRNA
expression.
For the numerous CNS structures containing robust
ORL1 mRNA expression, while having minimal or no OFQ
binding, several possible explanations for this disparity
exist. Although ORL1 mRNA is transcribed in cell bodies
within these structures, the ORL1 receptor may not be
translated, and therefore not available for binding. These
could also be regions where inactive orphanin receptor is
made, and unavailable for binding. Most likely however,
these are regions where ORL1 is produced in neuronal cell
bodies, transported, and incorporated into the cell mem-
brane at a site distal from the cell bodies containing
orphanin receptor mRNA. Although there are many fewer
structures in which OFQ binding is robust while ORL1
mRNA expression is absent, these too are most likely
regions where ORL1 receptor has been transported.
This mismatch in receptor mRNA and agonist binding
also has been observed in the opioid receptor system
(Mansour et al., 1993, 1994a,b, 1995b), where it is also
thought that such a mismatch provides evidence for opioid
receptor trafficking (Mansour et al., 1995b). In the orpha-
nin system, this explanation also likely holds true. Regions
where there is a strong correlation between OFQ binding
and ORL1 mRNA expression likely represent areas of local
receptor synthesis. In regions of poor correlation, receptor
transport is most likely. For example, several cranial nerve
nuclei contain robust ORL1 mRNA expression, with negli-
gible or no receptor binding sites. This suggests that the
ORL1 receptors are synthesized in cells of the red and
facial nuclei, for example, and transported to their termi-
nals where they are localized presynaptically. Similar to
what has been observed in the µ, k, and d opioid receptor
system (Mansour et al., 1995b), ORL1 receptor mRNA
expression is low in superficial and moderate in deeper
layers of the dorsal horn of the spinal cord. This expression
is robust in the ventral laminae, and high in the dorsal root
ganglia. In contrast, OFQ binding is densest in the superfi-
cial and deep dorsal horn layers, low in the ventral horn,
and absent in the dorsal root ganglia. A likely explanation
for these findings is that receptors expressed in the deeper
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layers of the dorsal horn are probably postsynaptic, and
those in the superficial laminae probably reside on presyn-
aptic fibers originating from the dorsal root. Orphanin
receptor-containing cells in the ventral horn most likely
transport ORL1 receptor to a distal site where they act
presynaptically.
Comparisons with ORL1-like immunolabeling
Anton et al. (1996) has reported a detailed distribution
of the immunohistochemical localization of the ORL1
receptor. This study did not include an analysis of ORL1
mRNA distribution or OFQ binding, but rather focused on
the distribution of the receptor protein. The ORL1 receptor
monoclonal antibody used by Anton et al. was also used in
a recent report comparing ORL1 and µ opioid receptor
distributions in pain processing regions of the brain (Mon-
teillet-Agius et al., 1998). We have spoken with the senior
author of the Anton study (Chris Evans, PhD). He has
informed us that recent studies that used his ORL1
monoclonal antibody in ORL1 knockout mice have raised
doubts concerning the specificity of this antiserum and he
encouraged us to present these concerns as part of this
discussion. It appears that this antibody still generates
significant immunoreactivity in ORL1 knockout mice,
suggesting the presence of at least two epitopes in the CNS
that this antiserum is recognizing, one epitope being ORL1
and the other(s) unknown (Chris J. Evans, personal com-
munication). Although these recent findings raise ques-
tions concerning the specificity of the antiserum used by
Anton et al. (1996), the pattern of distribution observed by
this group is in much agreement with ORL1 mRNA
distribution reported previously (Bunzow et al., 1994;
Fukuda et al., 1994; Lachowicz et al., 1994; Mollereau et
al., 1994; Wick et al., 1994) and with the findings of the
present study. Taking into account these concerns, compari-
sons made between our findings and those of the Anton
study should be made with caution. However, due to the
similarity in ORL1 distribution observed in our study and
that of Anton et al. (1996), brief comment will be made
regarding mismatch of receptor mRNA, protein, and bind-
ing distributions.
In concordance with our findings the authors found the
orphanin receptor to be distributed throughout a wide
range of the rat CNS, with most staining confined to fibers
and puncta. Orphanin receptor immunoreactivity in neuro-
nal cell bodies was observed only in the hilus of the dentate
gyrus in the forebrain, in the red nucleus, pontine reticular
nucleus, gigantocellular reticular nucleus and paragigan-
tocellular reticular nucleus in the brainstem, and in
laminae VIII and IX, the intermediolateral cell column,
dorsal nucleus, and lateral cervical nucleus of the spinal
cord. All of the above structures contain variable ORL1
mRNA expression, ranging from sparse in the dentate
hilum, paragigantocellular reticular nucleus, and lateral
cervical nucleus, to high in the red nucleus, caudal pontine
reticular nucleus, laminae VIII and IX of the ventral horn,
and intermediolateral cell column. However, in all of these
structures, OFQ binding is very sparse to undetectable.
These regions most likely represent areas where abundant
mRNA is translated into ORL1 receptor protein that is
transported distally, rather than being incorporated in the
cell body as a postsynaptic receptor. Interestingly, in no
region where ORL1 receptor immunoreactivity was de-
tected with cell bodies was significant 125I-[14Tyr]-OFQ
binding also observed. However, mRNA expression was
present in all these congruent structures. Colchicine was
not used in the study by Anton et al. (1996), and had axonal
transport been inhibited, it is possible that many more
regions with ORL1-containing cells expressing both mRNA
and receptor protein would be observed.
Assuming that most ORL1 receptor protein observed by
immunohistochemistry is specific (see above) and repre-
sents regions where active receptor is incorporated into
neuronal cell membranes, we expect that the distribution
of 125I-[14Tyr]-OFQ binding should correlate well with the
distribution of ORL1-like immunoreactivity (Anton et al.,
1996). Indeed, this is generally the case, as 125I-[14Tyr]-
OFQ binding analyzed in the present study correlates
extremely well with previously reported ORL1-like immu-
noreactivity. Orphanin receptor protein and binding are
both widely distributed throughout the CNS, with only few
areas of mismatch in our findings.
In the indusium griseum, subfornical organ, several
thalamic nuclei (ventrolateral, ventral posteromedial, ven-
tral posterolateral, interanteromedial, laterodorsal, lat-
eral geniculate, and paraventricular), and the tuber ci-
nereum, no ORL1-like immunoreactivity was observed but
significant OFQ binding was present. No such regions of
mismatch were observed in the brainstem or spinal cord.
This finding was especially evident in the thalamus, where
moderate to dense OFQ binding was observed in multiple
nuclei, whereas ORL1-like immunoreactivity was absent
in many regions and low in most others. There are several
CNS structures where ORL1-like immunoreactivity is
light, whereas 125I-[14Tyr]-OFQ binding is dense. These
may represent regions where receptor protein is not as
detectable as OFQ binding by the methods used. Regions
where no receptor protein is detected but binding is
detectable are very few. Other than several thalamic
nuclei, only three other structures in the CNS that contain
OFQ binding also lack ORL1 immunoreactivity. Given
that ORL1 immunoreactivity is very weak throughout the
thalamus, whereas OFQ binding is high, it is possible that
this particular region may have mismatch solely due to
limits of sensitivity in detecting ORL1 immunoreactivity
in this region, even when considering probable lack of
specificity of the ORL1 antiserum. Orphanin FQ binding is
robust and specific in this region, and ORL1 mRNA
expression is present and high in many thalamic nuclei as
well. Although Anton et al. (1996) did not find ORL1-like
immunoreactivity in high quantities in the thalamus,
most likely the receptor protein is present. Alternatively,
the presence of binding and no protein may suggest the
existence of multiple receptor subtypes that have yet to be
cloned. Further studies are needed to more closely exam-
ine this possibility.
Finally, there are some structures for which 125I-[14Tyr]-
OFQ binding is not detectable, but ORL1-like immunoreac-
tivity is present in significant amounts. These structures
include the islands of Calleja, basal nucleus of Meynert,
endopiriform nucleus, basomedial, central and posterolat-
eral cortical amygdaloid nuclei, stratum radiatum and
stratum pyramidal of areas CA1–CA3 of Ammon’s horn,
the granular layer of the dentate gyrus, trochlear nucleus,
rostral interpeduncular nucleus, deep mesencephalic
nucleus, retrorubral field, Kolliker-Fuse nucleus, pos-
terodorsal tegmental nucleus, laminae I and IX of the
spinal cord, and the lateral cervical nucleus. Again, this
may represent areas of nonspecific ORL1 immunoreactiv-
ity (see above). However, these regions may also represent
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areas where the ORL1 protein is present but being trans-
ported and not yet incorporated into cell membranes as
active receptor. These may also be regions of inactive ORL1
receptor in the CNS. In general, despite the recent evidence
questioning the specificity of the ORL1 monoclonal antiserum
(Chris J. Evans, personal communication), structures where
mismatches were observed were only a small proportion,
accounting for less than 8% of the total structures analyzed.
Comparisons with endogenous
opioid systems
The orphanin FQ receptor is known to differ from known
opioid receptors in its structure and distribution (Chen et
al., 1994; Fukuda et al., 1994; Lachowicz et al., 1994) and
its interactions with known opioid agonists (Meng et al.,
1996; Sim et al., 1996; Ma et al., 1997). As reported in the
present study, the distribution of the ORL1 receptor is
distinct from that of other opioid receptors. The distribu-
tion of the endogenous opioid peptide precursors, pro-
opiomelanocortin, proenkephalin, and prodynorphin, has
been studied in detail (Kachaturian et al., 1985), as has the
distribution of corresponding µ, k, and d receptors (Man-
sour et al., 1987, 1993, 1994a–d, 1995a,b, 1996). Correla-
tions between the distribution of the endogenous opioid
systems and orphanin FQ (mRNA and peptide) has been
discussed previously (Neal et al., 1999). In the present
discussion, we will focus on the relationship of 125I-[14Tyr]-
OFQ binding and opioid peptide and receptor systems as
possible sites of opioid modulation by ORL1 activation. It
is important to emphasize at this point that the possible
modulation of opioid and orphanin systems by one another
is not direct, because opioid peptides have essentially no
affinity for the orphanin receptor (Bunzow et al., 1994;
Chen et al., 1994; Fukuda et al., 1994; Lachowicz et al.,
1994; Wick et al., 1994; Ma et al., 1997; Nicholson et al.,
1998), and orphanin FQ has no affinity for the known
opioid receptors (Reinscheid et al., 1995). There may be
some physiologic interactions, however, due to their pos-
sible localization in or interactions with the same neuronal
cell body or process.
Pro-opiomelanocortin and the µ receptor. Pro-
opiomelanocortin gives rise to the endogenous opioid b-en-
dorphin. Although this neuropeptide has a very limited
CNS neuronal distribution, b-endorphin-containing fibers
are widely distributed (Kachaturian et al., 1985). The µ
opioid receptor, like b-endorphin, is widely distributed
within fibers in the CNS, but it also has a much broader
distribution within cell bodies (Mansour et al., 1987,
1994a, 1995a,b).
Moderate 125I-[14Tyr]-OFQ binding is observed in the
arcuate nucleus, and dense binding is observed in the
nucleus of the solitary tract, both structures with b-endor-
phin-containing cell bodies. In the bed nucleus of the stria
terminalis, medial amygdala, dorsomedial hypothalamus,
paraventricular thalamic nucleus, central gray, raphe
system, lateral parabrachial nucleus, and nucleus of the
solitary tract, orphanin binding is dense and may play a
modulatory role on neurotransmitter release from b-endor-
phin-containing fibers.
Similarly, µ and ORL1 receptor binding are both dense
in the neocortex, medial amygdala, dentate gyrus, thala-
mus, substantia nigra, pars compacta, superior colliculus,
parabrachial nucleus, nucleus ambiguous, solitary nucleus,
spinal trigeminal nucleus, and lamina II of the spinal
dorsal horn. Similar to possible modulatory effects on the
b-endorphin system, the orphanin system may modulate µ
receptor effects in these regions. In addition, activation of
the µ receptor could modulate ORL1 receptor effects in
these regions as well. In support of a possible inhibitory
role for OFQ on this system, it has been demonstrated that
orphanin FQ can inhibit b-endorphin neurons and secre-
tory cells in the arcuate by means of activation of inward
K1 currents (Wagner et al., 1998). Orphanin FQ has also
been shown to inhibit dorsal raphe and central gray
neurons by a similar mechanism (Vaughan and Christie,
1996; Vaughan et al., 1997).
Prodynorphin and the k receptor. Prodynorphin-
containing cell bodies and fibers are widely distributed
throughout the CNS (Kachaturian et al., 1985; Mansour et
al., 1994b), and k receptor localization and binding is also
quite widespread (Mansour et al., 1987, 1994b,c, 1995b,
1996). There are several regions where moderate to dense
125I-[14Tyr]-OFQ binding could coexist with dynorphin-
containing cell bodies, including the dentate gyrus, the
arcuate and ventromedial hypothalamic nuclei, central
gray, parabrachial nucleus, nucleus of the solitary tract,
caudal spinal trigeminal nucleus, and dorsal horn of the
spinal cord. Within the CA3 region of Ammon’s horn, the
central gray, lateral parabrachial nucleus, caudal spinal
trigeminal nucleus, nucleus of the solitary tract, and
dorsal horn of the spinal cord, dynorphin fiber labeling and
ORL1 receptor binding are high. In these regions, ORL1
receptor activation may directly influence the dynorphin
system. Within the medial preoptic area, bed nucleus of
the stria terminalis, paraventricular thalamic nucleus,
medial nucleus of the amygdala, ventromedial hypothala-
mus, superficial gray layer of the superior colliculus,
central gray, dorsal raphe, parabrachial nucleus, nucleus
of the solitary tract, and spinal trigeminal nucleus, dense
125I-[14Tyr]-OFQ binding and robust k receptor localization
and binding is observed. These areas provide sites for
possible cross-modulation of ORL1 and k activation within
these structures. To date, a direct effect of orphanin FQ on
dynorphin production or release or on k receptor activation
has not been demonstrated.
Proenkephalin and the d receptor. Proenkephalin is
the most widely distributed of the endogenous opioid
peptides, but with a limited distribution in the brainstem
(Kachaturian et al., 1985). In contrast, the d receptor is
less widely distributed than the other opioid receptors
(Mansour et al., 1987, 1993, 1995b).
The function of enkephalin-containing neurons could be
influenced by OFQ activation of the ORL1 receptor in
many regions where both are expressed. Such regions
include the cingulate and piriform cortices, paraventricu-
lar and arcuate nuclei of the hypothalamus, hippocampal
formation, central gray, paramedian raphe and raphe
magnus, solitary nucleus, spinal trigeminal nucleus, and
dorsal horn of the spinal cord. Enkephalin-containing
fibers in the ventromedial nucleus of the hypothalamus,
hippocampal formation, central gray, interpeduncular
nucleus, solitary nucleus, and dorsal horn of the spinal
cord are also within regions where OFQ binding is present,
providing another milieu where orphanin modulation of
enkephalin peptide may occur by means of ORL1 activa-
tion. Interestingly, orphanin FQ has been shown to modu-
late enkephalin release in myenteric plexus preparations
(Gintzler et al., 1997), providing evidence that such an
interaction could occur in the CNS as well. The ventrome-
dial nucleus of the hypothalamus, medial nucleus of the
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amygdala, interpeduncular nucleus, spinal trigeminal
nucleus, and substantia gelatinosa of the dorsal horn
contain dense ORL1 and d receptor binding. This codistri-
bution of ORL1 and d receptor binding provides sites for
possible cross-modulation of d and ORL1 receptor activa-
tion in these regions.
Orphanin FQ and ORL1 receptor circuitry
Although ORL1 receptor mRNA and 125I-[14Tyr]-OFQ
binding distribution differs markedly from that of the OFQ
peptide, on closer analysis, multiple anatomic circuits
become evident where peptide-receptor interactions may
provide insights into functional roles for this new orphanin
system. A detailed discussion of these functional implica-
tions with respect to the distribution of OFQ and the ORL1
receptor has been published recently (Neal et al., 1999).
Therefore, this discussion will not attempt to repeat the
previous exhaustive review but will instead discuss pos-
sible roles of orphanin FQ in selected anatomic systems.
Cortical systems. Within the cerebral cortex, dense
ORL1 receptor binding is observed, particularly in layers
IV–VI. In addition, OFQ peptide and mRNA are also
heavily distributed in the neocortex in layers II, III, V, and
VI (Neal et al., 1999). This diffuse pattern of OFQ and
ORL1 distribution provides evidence of involvement of the
orphanin system in cortical input and output circuits. One
example of such an influence is on cortical noradrenergic
input. It has been demonstrated recently that orphanin
may inhibit noradrenaline release in the cortex by means
of presynaptic ORL1 receptors (Schlicker et al., 1998).
Thalamic input into the cortex may also be a source of
orphanin modulation. However, OFQ levels observed in
the thalamus are very low, and orphanin-containing neu-
rons that are identified in the thalamus reside in struc-
tures that tend to have limbic connections, such as the
anteroventral, paratenial, and paraventricular nuclei (Neal
et al., 1999). One notable exception to this trend is the
OFQ mRNA expression observed in the posterior thalamic
group and suprageniculate nucleus. This region of the
thalamus receives spinothalamic fibers and has been
shown to be involved in the perception of painful stimuli in
the monkey. Neurons within this region are known to
project directly to somatosensory cortical areas (Bowsher,
1961; Kerr, 1975; Boivie, 1979), making this one of several
areas where OFQ may play a role in pain modulation.
It is of interest to note that the claustrum contains
strong OFQ immunoreactivity and mRNA expression and
dense ORL1 binding. Although, traditionally thought of as
a basal ganglia structure, this telencephalic cell group has
widespread reciprocal connections with the neocortex
(Norita, 1977), bearing more resemblance with the thala-
mus than with the basal ganglia. Corticoclaustral projec-
tions arise from pyramidal cells in layer VI of the neocor-
tex, and projections from the claustrum terminate mostly
in layer IV of the neocortex (Olson and Graybiel, 1980;
Sherk and Levay, 1981a,b). Cortical layer VI contains
abundant OFQ binding, and OFQ peptide is in abundance
in cell bodies in the claustrum, providing the framework
for reciprocal cortical and claustral circuitry.
Mesolimbic systems Although OFQ expression within
cell bodies in the nucleus accumbens is negligible, it is
important to note that fiber labeling within this structure
is quite dense, particularly in the rostral pole and core.
Although the shell and core have been reported to contain
a moderate amount of ORL1 immunoreactivity in fiber
processes (Anton et al., 1996), 125I-[14Tyr]-OFQ binding
observed in the accumbens core and shell is light. Afferents
into the accumbens core differ markedly from those into
the shell, which had much less OFQ fiber immunolabeling
(Zahm and Brog, 1992; Brog et al., 1993). Major afferents
to this region include the basolateral amygdala, entorhinal
cortex, intralaminar thalamic nuclei, ventral tegmental
area and dorsal raphe, regions with prominent OFQ
immunoreactivity, and mRNA content (Neal et al., 1999).
Little is known concerning the behavioral effects of OFQ in
relation to these regions, but it may play a role in
modulation of both motivational and motor-related behav-
iors. In support of a functional role for the orphanin system
in this circuitry, injections of orphanin FQ into the lateral
ventricle of the rat has been shown to suppress dopamine
release in the nucleus accumbens (Murphy et al., 1996).
Interestingly, although rats have been shown to develop
tolerance to locomotor effects induced by orphanin (Devine
et al., 1996a), they fail to demonstrate conditioned place
preference when given intraventricular injections of this
peptide (Devine et al., 1996b). However, the inability to
generate conditioned place preference or aversion in ear-
lier studies in the rat may have been limited again by
locomotor effects of this peptide. The presence of OFQ
within this ventral tegmental-accumbens circuitry may
point to a modulatory role for this peptide in behavioral
reinforcement.
Extended amygdala. It has been proposed that the
bed nucleus of the stria terminalis provides a major output
point for the extended amygdala complex (Alheid et al.,
1995). In this model, the medial nucleus of the amygdala is
intimately related with the medial division of the stria
terminalis and the central nucleus is reciprocally con-
nected with the lateral division of the bed nucleus of the
stria terminalis and the shell of nucleus accumbens.
Orphanin FQ peptide immunoreactivity is high in the
medial and central amygdaloid nuclei, and both the medial
and lateral divisions of the bed nucleus of the stria
terminalis (Neal et al., 1999). Orphanin receptor binding is
negligible in the central amygdaloid nucleus but is dense
in the medial and lateral divisions of the bed nucleus of the
stria terminalis and the medial nucleus of the amygdala.
The presence of OFQ within these structures provides a
source of orphanin influence in many functional systems.
For example, the medial extended amygdala with the
medial division of the bed nucleus of the stria terminalis
are known to have efferents to the medial preoptic area
and anterior hypothalamus, medial thalamic nuclear group,
and multiple hypothalamic nuclei. Orphanin receptor bind-
ing is robust within these regions, providing support for a
broad range of orphanin influence in motor control, auto-
nomic responses, and specific behavioral patterns (motiva-
tional, sexual, feeding, and defensive behaviors).
Preoptic and hypothalamic circuits. The medial
preoptic-anterior hypothalamic area and ventromedial
nucleus of the hypothalamus receive strong input from the
extended amygdala, and both demonstrate dense ORL1
binding. In addition, the medial preoptic area contains
moderate OFQ neuronal, fiber, and terminal labeling
(Neal et al., 1999). The ventromedial hypothalamus is
devoid of OFQ-containing neurons but has a moderate
plexus of orphanin FQ fibers and terminals and demon-
strates high levels of OFQ binding. The medial preoptic
area receives inputs from the medial nucleus of the
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amygdala and medial bed nucleus of the stria terminalis
(medial extended amygdala), arcuate nucleus, lateral sep-
tum, ventral tegmental area, parabrachial nucleus, and
nucleus of the solitary tract, all regions with OFQ-
containing neurons. Output of the medial preoptic area is
extensive and plays a major role in neuroendocrine, auto-
nomic, and somatosensory responses responsible for highly
integrated maternal and mating behaviors (Simerly, 1995).
The ventromedial nucleus of the hypothalamus contains
some of the most dense ORL1 mRNA expression and OFQ
binding in the CNS. It receives strong inputs from the
ventral subiculum and medial amygdala, both of which
contain abundant orphanin FQ immunoreactivity. It also
receives multiple afferents from the hypothalamus and
parabrachial nucleus. Most afferents to the ventromedial
nucleus originate in structures with OFQ-containing neu-
rons. Efferents from this nucleus project to the lateral
septum, bed nucleus of the stria terminalis, medial nucleus
of the amygdala, and medial preoptic area. There is an
extensive representation of OFQ and ORL1 receptor bind-
ing in nuclei involved with the medial preoptic area-
anterior hypothalamus and the ventromedial nucleus of
the hypothalamus. This organization makes it likely that
OFQ may play a role in modulation of ingestive, affective,
and sexual behavior. In support of this notion, several of
these regions contain neurons expressing estrogen recep-
tors and are highly involved in sexual behavior (Canteras
et al., 1994). In addition, orphanin FQ has been shown to
stimulate feeding and ingestive behavior in rats (Pomonis
et al., 1996; Stratford et al., 1997), and orphanin injections
into the ventromedial hypothalamus induces lordosis in
female rats (Sinchak et al., 1997).
The paraventricular hypothalamic nucleus has only
light to moderate orphanin-like immunoreactivity, but it
does contain high ORL1 mRNA expression and binding.
This nucleus is critical in the hypothalamo-pituitary-
adrenocortical axis, and it receives afferent input from
several structures with orphanin-like immunoreactivity
(Herman and Cullinan, 1997). Brainstem afferents, provid-
ing input related to autonomic function, include the A1 cell
group in the ventrolateral medulla, the A2 cell group and
the locus coeruleus (A6 cell group), which projects to the
more medial part of the parvicellular paraventricular
nucleus, where orphanin fiber labeling is heaviest. The
nucleus of the solitary tract also has nonadrenergic input
into this structure. Forebrain regions with projections to
the paraventricular nucleus include the subfornical organ,
median preoptic nucleus, anteroventral periventricular
nucleus, arcuate nucleus, dorsomedial nucleus lateral
hypothalamus, medial preoptic area, bed nucleus of the
stria terminalis, medial nucleus of the amygdala, and
central nucleus of the amygdala (Herman and Cullinan,
1997). These paraventricular inputs are extensive, and
OFQ is prominent in most of the regions that give rise to
these afferents. Given the presence of ORL1 binding
throughout the paraventricular nucleus, the orphanin
system most likely plays a modulatory role in this struc-
ture. Little evidence to date supports a role for orphanin in
the stress response, but it has been shown to have an
anxiolytic effect in rat (Jenck et al., 1997).
Hippocampal formation. The lateral septum con-
tains robust orphanin peptide mRNA expression and neu-
ronal immunoreactivity. The efferent and afferent connec-
tions of the lateral septum are confined to very discreet
forebrain regions (Swanson and Cowan, 1979; Jakab and
Leranth, 1995). All parts of the lateral septal nucleus
receive heavy input from the hippocampal formation.
Additional afferents arise from the bed nucleus of the stria
terminalis, medial amygdaloid nucleus, and pontine teg-
mentum. Orphanin FQ immunoreactivity is very intense
in these regions, and ORL1 receptor binding is present in
the lateral septal region. More importantly, the lateral
septal region, with its high OFQ content, has efferent
projections to several regions where ORL1 binding is
present. These structures include the medial preoptic
area, anterior and lateral hypothalamic areas, dorsome-
dial hypothalamus, supramammillary region, and medial
nucleus of the amygdala. This ORL1 and OFQ distribution
pattern provides support for a role of OFQ in the function
of this limbic structure and interactions with the hippocam-
pus.
Orphanin binding and ORL1 mRNA expression, and
OFQ expression in the hippocampal formation are widely
distributed (Neal et al., 1999). Strongest OFQ immunola-
beling and mRNA expression is observed in the pyramidal
layer of area CA1 of Ammon’s horn, stratum lucidum of
area CA3, the granule cell layer of the dentate gyrus, and
the subiculum. The overall intrinsic and extrinsic connec-
tions and efferent projections of the hippocampal forma-
tion have been studied in detail (Swanson and Cowan,
1977; Amaral and Witter, 1995). The dentate gyrus re-
ceives afferent input from the medial septum, diagonal
band, supramammillary nucleus, lateral hypothalamus,
locus coeruleus, and raphe nuclei. With the exception of
the medial septum, these structures contain abundant
OFQ peptide. Numerous neurons expressing mRNA for
the ORL1 receptor are localized within the granule layer of
the dentate gyrus, whereas binding is confined to the
molecular layer. Orphanin FQ immunolabeling and mRNA
expression within the dentate gyrus is confined mostly to
the granule cell layer. Basket cells within this layer
provide dendritic fibers that form contacts with cells
within the molecular layer where this OFQ binding is
robust.
Ammon’s horn contains dense ORL1 binding, primarily
in stratum oriens of CA2 and CA3, with lower levels of
binding in stratum lucidum and radiatum. Area CA3
receives major input from the medial septum and diagonal
band, primarily into stratum oriens, where OFQ binding is
dense. The intrinsic connections of area CA2 are very
similar to that of CA3, except that this region also receives
prominent input from the tuberomammillary nucleus and
supramammillary area, regions with several OFQ-contain-
ing neurons present. The subiculum has robust orphanin-
like immunoreactivity. Its extrinsic efferents are extensive
and this structure contains dense ORL1 receptor binding.
Its primary afferents originate in the medial septum-
diagonal band complex, posterior cortical and basal amyg-
daloid nuclei, reuniens thalamic nucleus, supramammil-
lary region, ventral tegmental area, locus coeruleus, and
raphe complex. Many of these structures express OFQ in
perikarya, and orphanin may be providing modulatory
input to the subiculum through many of these structures.
Orphanin-containing cell bodies in the subiculum could
influence many structures, as the subiculum is one of the
major output regions of the hippocampal formation, and
most of the regions to which it projects are rich in orphanin
binding.
The role of orphanin in the hippocampus is presently not
clear. However, orphanin has been reported to reversibly
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inhibit voltage-gated calcium channels in pyramidal neu-
rons from area CA1 and CA3 (Knoflach et al., 1996) and to
inhibit synaptic transmission and long-term potentiation
in area CA1 of Ammon’s horn and the dentate gyrus (Yu et
al., 1997). The latter effect is thought to be presynaptic in
nature. Microinjection of OFQ into the CA3 region of adult
rats has been shown to impair spatial learning (Sandin et
al., 1997). These findings remain controversial, because
effects of orphanin on motor behavior were not taken into
account (see below). However, in support of the findings by
Sandin et al. (1997), a recent study on knockout mice
lacking the orphanin receptor demonstrated enhancement
of spatial attention in the water-finding test (Mamiya et
al., 1998). Initial studies clearly support a role for this
peptide in learning and memory function, and its anatomic
distribution supports this concept as well.
Thalamus. In general, ORL1 receptor binding is
prominent in the thalamus, but OFQ expression is very
low, with peptide and mRNA expression mostly confined to
the paraventricular nucleus, paratenial nucleus, posterior
nucleus, reticular nucleus, zona incerta, and medial ha-
benula. The reticular thalamic nucleus contains high
orphanin mRNA and peptide expression, and moderate
ORL1 receptor mRNAexpression and binding. This nucleus
has an abundance of GABA-ergic neurons and receives
inputs from both thalamocortical and corticothalamic fi-
bers (Price, 1995). Thalamocortical cells in each nucleus of
the dorsal, intralaminar, and anterior thalamic group
projects to the cortex and to a restricted part of the
reticular nucleus, which in turn projects back to that
specific nucleus. Brainstem inputs into this nucleus and
reciprocal projections with specific thalamic nuclei may
play a role in the sleep-wake cycle, and orphanin may be
involved in modulation of this system.
The zona incerta, a perithalamic structure lying at the
ventral extension of the reticular thalamic nucleus, has
numerous orphanin-containing cells and fibers, and moder-
ate orphanin binding. This structure has direct projections
to the parabrachial nucleus and spinal cord, regions with
dense ORL1 receptor binding. The afferent projections into
this nucleus and possible functions remains unclear, but
stimulation of this structure does lower heart rate and
blood pressure (Spencer et al., 1988), supporting a role for
orphanin in cardiovascular control. In support of this
notion, ORL1 activation has been shown to decrease blood
pressure and cardiac output (Champion and Kadowitz,
1997a,b; Champion et al., 1997; Gumusel et al., 1997) and
to inhibit cardiomotor neurons in the rostral ventrolateral
medulla (Chu et al., 1998) in rats. Orphanin’s effects on
blood pressure may be by means of direct vasodilatation of
the arterial bed, probably by means of dilation of resis-
tance arteries (Champion et al., 1998)
Tectum and pretectum. Orphanin FQ receptor mRNA
and binding, and OFQ peptide are observed throughout
several visual system nuclei in the mesencephalon, includ-
ing the pretectum, the nucleus of Darkschewitsch, and the
superior colliculus. Although orphanin peptide is observed
throughout the pretectal region, ORL1 binding is mostly
confined to the olivary pretectal nucleus. This nucleus
receives strong bilateral retinal inputs, with smaller in-
puts from the cerebral cortex and lateral geniculate
nucleus, and it appears to be involved in mediation of the
light reflex, because electrical stimulation of this nucleus
induces pupillary constriction (Trejo and Cicerone, 1984;
Sefton and Dreher, 1995). The nucleus of Darkschewitsch
has the heaviest orphanin peptide and mRNA content in
the midbrain. This nucleus receives afferent input from
the superior colliculus, deep cerebellar nuclei, and preposi-
tus hypoglossus and is thought to be involved with integra-
tion of visual information (Steiger and Büttner-Ennever,
1979). The efferent projections of this nucleus are not well
understood, so although orphanin peptide and mRNA
content is very high in this nucleus, what role OFQ plays
in its circuitry is unclear.
The superior colliculus contains only scattered OFQ
immunoreactivity, confined primarily to the optic nerve
and intermediate gray layers, but very high levels of
binding are noted in its zonal and superficial gray layers.
The afferents and efferents of the superior colliculus are
numerous and complex (Sefton and Dreher, 1995), and
generally, afferents to the superficial layers originate in
the cortex, pretectum, lateral geniculate body, raphe sys-
tem, locus coeruleus, and prepositus hypoglossus. Most of
these structures have abundant OFQ content that may
directly activate ORL1 receptors in the zonal or superficial
gray layers. Efferents from this region are primarily to the
intralaminar nuclei of the thalamus, medial pons, me-
dulla, and spinal cord, in regions involved with orienting
reactions and eye movements. Although orphanin content
within these regions is moderate, receptor content is high,
implicating this peptide for a modulatory role in orienta-
tion to visual stimuli.
The anterior pretectal nucleus receives strong inputs
from other pretectal nuclei, but does not receive direct
retinal inputs (Sefton and Dreher, 1995). This nucleus
receives inputs from the superior colliculus and parabigemi-
nal nucleus, and appears to be involved in nociception,
because very low levels of electrical stimulation are re-
quired for antinociception in its rostral division adjacent to
the central gray (Rees and Roberts, 1993). Some ORL1
binding is present in this structure, and OFQ content is
prominent (Neal et al., 1999), supporting a possible role for
the orphanin system in the antinociceptive activities ob-
served in this region.
Central gray. The central gray contains prominent
ORL1 mRNA expression and receptor binding, and robust
OFQ expression. The afferent inputs to this structure are
numerous and include the cingulate, insular, perirhinal,
and frontal cortices, preoptic region, hypothalamus, zona
incerta, amygdala, anterior pretectal nucleus, superior
and inferior colliculus, deep mesencephalic nuclei, parabra-
chial nucleus, dorsal raphe and raphe magnus, locus
coeruleus and A5 noradrenergic cell group, cerebellum,
prepositus hypoglossus, cuneiform nucleus, lateral paragi-
gantocellular nucleus, spinal trigeminal nucleus and spi-
nal cord (Beitz, 1982). Most of these structures providing
input into the central gray contain OFQ-expressing neu-
rons. Efferent of this region are equally as numerous, with
ascending projections to the fields of Forel, zona incerta,
lateral septum, nucleus accumbens, olfactory tubercle,
frontal cortex, midline and intralaminar thalamic nuclei,
preoptic area, numerous hypothalamic nuclei, cuneiform
nucleus, pedunculopontine tegmental nucleus, dorsal ra-
phe, deep mesencephalic nucleus, ventral tegmental
nucleus, subcoeruleus, interstitial nucleus of the medial
longitudinal fasciculus, pontine reticular nucleus, ventro-
medial medulla, and the raphe magnus (Eberhart et al.,
1985; Beitz et al., 1988). Most structures receiving central
gray inputs contain ORL1 receptor binding. Such a pres-
ence of ORL1 and OFQ in the central gray provides
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support for a strong OFQ influence on the proposed role of
the central gray in responding to potentially threatening
stimuli, by means of direct effects on antinociception,
vocalization, and defensive reactions.
Serotoninergic and noradrenergic systems. Orpha-
nin receptor mRNA expression and binding, and OFQ
expression are prominent in the serotonergic raphe nuclei
and the noradrenergic-containing locus coeruleus and A5
cell groups. The anatomy of the A5 cell group is less known
than that of the locus coeruleus. The A5 cell group has no
forebrain projections but does project to autonomic nuclei
of the brainstem and spinal cord (Byrum and Guyenet,
1987). Orphanin FQ binding is observed in this cell region,
providing a possible modulatory role in A5 control of
autonomic function. The locus coeruleus contains numer-
ous OFQ- and ORL1-expressing neurons, with very dense
binding. Within this nucleus, virtually every neuron is
noradrenergic (Aston-Jones et al., 1995), making it highly
likely that ORL1- or OFQ-containing neurons within this
nucleus colocalize with noradrenaline. Major afferents into
this nucleus include primarily the lateral paragigantocel-
lular reticular nucleus, prepositus hypoglossus, paraven-
tricular nucleus of the hypothalamus, A5 cell group, and
median raphe (Aston-Jones et al., 1995). These structures
providing major inputs into locus coeruleus are also OFQ-
containing regions. Efferents from this nucleus are exten-
sive, including projections into olfactory structures, the
neocortex, hippocampus, several thalamic nuclei, the stria-
tum, medial septum, diagonal band, bed nucleus of the
stria terminalis, medial preoptic area, paraventricular
nucleus of the hypothalamus, midbrain tectum, central
gray, interpeduncular nucleus, cerebellum, and multiple
sensory and association nuclei within the pons and me-
dulla (Aston-Jones et al., 1995). Orphanin FQ has been
shown to activate inwardly rectifying potassium currents
by means of the ORL1 receptor in locus coeruleus neurons
(Connor et al., 1996), providing direct evidence for OFQ
modulation of locus coeruleus function. In this manner,
OFQ may influence locus coeruleus control of multiple
autonomic and behavioral functions.
Orphanin FQ and orphanin receptor binding are promi-
nent in all serotonin-containing raphe regions, including
the dorsal raphe, caudal linear raphe, median raphe,
raphe pallidus, raphe magnus, and raphe obscurus. The
serotonin system provides extensive projections through-
out the CNS, with ascending projections to the olfactory
bulb, septal area, striatum, globus pallidus, claustrum,
bed nucleus of the stria terminalis, nucleus accumbens,
medial preoptic nucleus, suprachiasmatic nucleus, dorsal
and ventral premammillary nuclei, subfornical organ,
intralaminar and midline thalamic nuclei, the hippocam-
pal formation, and the neocortex. Descending projections
are to laminae I, II, and X of the spinal cord and ventral
horn neurons, the reticular formation, solitary nucleus,
cranial nerve nuclei, inferior olivary complex, parabra-
chial nucleus, cerebellum granule cell layer, superior
colliculus, interpeduncular nucleus, central gray, and dopa-
mine cell groups (Aitken and Törk, 1988; Halliday et al.,
1995). Although the ORL1 receptor is found in most of
these efferent target regions, dense ORL1 binding within
the raphe system supports a direct role for OFQ modula-
tion of serotonin-containing projection neurons within the
raphe complex. In this manner, OFQ could influence
numerous serotonergic functions, including autonomic con-
trol of blood pressure and sodium balance, sexual and
feeding behaviors, nociception, cognition, arousal, and
affective behaviors. In support of this finding, OFQ has
been shown to activate inwardly rectifying potassium
currents by means of the ORL1 receptor in dorsal raphe
neurons, similar to that demonstrated in the locus coer-
uleus (Vaughan and Christie, 1996).
Olivary complex and cerebellum. Orphanin receptor
and peptide content is very low in the cerebellum, confined
to the deep cerebellar nuclei. Afferent input into the medial
cerebellar nucleus is primarily from Purkinje cells within
the vermal cerebellar nucleus where no orphanin-contain-
ing neurons are noted. The medial nucleus, however, holds
numerous OFQ-containing neurons (Neal et al., 1999) and
has a diffuse efferent distribution to the deep layers of the
superior colliculus, the deep mesencephalic nucleus, the
supraoculomotor central gray, the medial accessory optic
nucleus, and the zona incerta (Ruigrok and Voogd, 1990),
all regions with ORL1 receptor binding.
Afferent inputs into the cerebellum by means of the
inferior olive also may provide orphanin influences. It is
important to note here that the inferior olive contains high
OFQ expression in its dorsal and principal parts and high
levels of ORL1 receptor binding. It receives afferents from
higher cortical centers and the red nucleus, with efferent
projections primarily to the lateral cerebellar hemispheres
(Azizi and Woodward, 1987). It is interesting to note that
the red nucleus contains high ORL1 mRNA expression,
but little receptor binding. The inferior olive is a likely
distal site where ORL1 receptor is transported from the
red nucleus. Orphanin binding within this region may
modulate olivary input to the cerebellar hemispheres,
further influencing balance and fine motor function.
In addition to the inferior olive, the vestibular nuclear
complex is intimately involved with cerebellar circuitry
and function, and several structures within this complex
express orphan peptide and receptor. Cerebellar nuclear
input to the vestibular complex arises primarily from the
fastigial (medial) cerebellar nucleus (Rubertone and Ha-
roian, 1982), which contains high levels of ORL1 and OFQ
expression. Other possible orphanin-containing afferent
input to these nuclei originate from contralateral vestibu-
lar nuclei, the reticular formation, B subnucleus of the
medial inferior olive, spinal trigeminal nucleus, pars ora-
lis, locus coeruleus, and neocortex. The efferent projections
of the vestibular nuclei are numerous and include many
areas with ORL1 receptor expression and binding (Ruber-
tone et al., 1995), including the spinal cord, oculomotor
and trochlear nuclei, several thalamic nuclei, including
the central lateral, ventrolateral, medial and lateral ven-
tral posterior nuclei, the medial geniculate nucleus, infe-
rior olive, and lateral paragigantocellular reticular nucleus.
Influences derived from these structures within the olivo-
cerebellar circuitry are involved in balance and adjust-
ments to proprioceptive cues. By means of this circuitry,
the orphanin system may be involved with integration of
multiple sensory inputs in refining motor behavior.
Reticular formation. The reticular formation of the
midbrain, pons, and medulla provides a substrate for
convergence and integration of multiple inputs from fiber
bundles traversing the brainstem in an ascending or
descending direction. Orphanin receptor mRNA and bind-
ing and OFQ peptide are highly expressed throughout
these structures, including the deep mesencephalic reticu-
lar nucleus, the pontine reticular nucleus, the parvicellu-
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lar reticular field, gigantocellular reticular field, ventral
gigantocellular reticular field, lateral reticular field, and
lateral paragigantocellular reticular nucleus. Projections
from these structures are widespread, and the ORL1
receptor is observed in most nuclei receiving reticular
afferents. If orphanin is indeed playing a modulatory role
within these centers, it may influence numerous functions,
including orienting movements of the eyes, head and body
by means of spinal cord projections, selective attention by
means of forebrain inputs into the dorsal thalamus, and
the general tonic ascending activating influence of this
system on the neocortex (Jones, 1995).
Spinal cord. The spinal cord contains abundant orpha-
nin peptide and mRNA (Neal et al., 1999) and also
expresses high levels of ORL1 receptor mRNA and bind-
ing. The highest OFQ expression is observed in laminae II,
III, IV, and X; ORL1 mRNA is highest in laminae VIII and
IX; and ORL1 binding is most abundant in laminae III, III,
and IV. Lamina II (substantia gelatinosa) neurons have
been shown to respond to brush and pinch stimuli (Woolf
and Fitzgerald, 1983), but only relatively few are known to
ascend to the ventrolateral reticular formation, lateral
cervical nucleus, and thalamus. Lamina III neurons re-
spond only to weak mechanical stimulation and many of
these neurons have been shown to project to other regions
within the same segment of the spinal cord, the dorsal
column nuclei, the lateral cervical nucleus, and the thala-
mus (Molander et al., 1989). In lamina IV, many of these
neurons only respond to light mechanical stimulation, but
many respond to nociceptive stimuli as well. Many of these
neurons project locally in the spinal cord, and also to the
lateral cervical nucleus and the thalamus. Orphanin-
containing neurons within these laminae may be involved
in local circuitry, projecting to laminae II and III where
ORL1 receptor binding is high. In addition, they may play
a modulatory role in efferent spinal cord projections in
response to mechanical and nociceptive input.
Lamina VII is the intermediate zone of the gray matter,
and some parts extend into the ventral horn. It contains
the intermediolateral and intermediomedial cell columns,
which contain no OFQ, but abundant ORL1 receptor
(Molander at al., 1989). Cells within this region respond
strongly to noxious stimuli and project to the brainstem,
thalamus, and hypothalamus (Nahin et al., 1983). The
heavy orphanin content within this region may provide an
orphanin influence on processing of noxious stimuli and
modulation of efferent relays from this region.
The possible modulatory role for orphanin in spinal cord
functions has been examined with respect to orphanin distribu-
tion by several investigators (Riedl et al., 1996; Lai et al., 1997;
Schuligoi et al., 1997), and orphanin does appear to be
intimately involved in the modulation of painful stimuli and
the release of endogenous opioids at the spinal level. Recent
evidence that used double label immunohistochemistry and
confocal microscopy has shown that ORL1 and µ opioid
receptor antisera label different fibers in areas involved in
pain processing, including dorsal root ganglia, superficial
laminae of the spinal cord, central gray, raphe magnus,
gigantocellular reticular nucleus, and nucleus of the solitary
tract (Monteillet-Agius et al., 1998). [It is important to note
again, however, that the specificity of the ORL1 antiserum
used is being questioned (see above).] Although orphanin
obviously plays a major role in nociception, its effects are
likely by means of spinal and supraspinal pathways
distinct from that of the endogenous opioid receptors.
CONCLUSIONS
We have demonstrated that, like orphanin FQ, the
ORL1 receptor is widely distributed throughout the CNS
of the adult male rat. We have also established a close
correlation between ORL1 receptor mRNA and 125I-[14Tyr]-
OFQ peptide binding. Additionally, the distribution of
125I-[14Tyr]-OFQ binding correlates well with the distribu-
tion of the ORL1 receptor protein as demonstrated by
immunohistochemistry (Anton et al., 1996), although there
are concerns regarding the specificity of the ORL1 monoclo-
nal antibody (see Comparisons With ORL1-Like Immuno-
labeling section). Orphanin FQ and the ORL1 receptor are
expressed in several CNS circuits, supporting its involve-
ment in multiple functional systems, including nocicep-
tion, modulation of the L-HPA stress axis, motivation and
reward, learning and memory, gross motor control, balance
and proprioception, sexual, aggressive and investigatory
behaviors, control of autonomic and physiologic functions,
and integration of special sensory input. The present
anatomic information on the distribution of the ORL1
receptor and the OFQ peptide (Neal et al., 1999) provide
the anatomic basis for understanding the many possible
behavioral and physiologic roles of this neuropeptide.
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